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Intercellular Adhesion Molecule 1 (ICAM-1) ein neuer 
Co-Rezeptor für c-Met 
ZUSAMMENFASSUNG 
Das Transmembranprotein CD44v6 wird in verschiedenen transformierten und 
normalen Zellen zur Aktivierung und Signalweiterleitung durch den „hepatocyte 
growth factor (HGF)“-Rezeptor c-Met benötigt. 
Kollaboriert der c-Met Rezeptor in Abwesenheit von CD44, z.B. in Hepatozyten 
oder in CD44 Knockout Mäusen, mit anderen Transmembranmolekülen um 
aktiviert zu werden und Signale weiterzuleiten? Die Idee, dass solche Moleküle 
existieren, die Funktionen von CD44 übernehmen können, stammt von CD44 
Knockout Mäusen, die im Grunde einen normalen Phenotyp aufweisen.  
Um einen alternativen Co-Rezeptor für c-Met zu finden, habe ich Merkmale von 
CD44v6 untersucht, die für die Aktivität von c-Met essentiell sind: (i) Modulation 
der c-Met Signaltransduktion durch die ERM Proteine (ezrin/radixin/moesin), die 
die Verbindung zum Aktinzytoskelett vermitteln, (ii) Repression der c-Met 
Aktivierung durch Hyaluronsäure (HA), einer Komponente der extrazellulären 
Matrix und (iii) Komplexbildung mit c-Met. 
Da ich mit Kompetitionsexperimenten und RNA Interferenz zeigen konnte, dass 
ERM Proteine in der c-Met Signalkaskade benötigt werden und dass HA in 
HepG2 Zellen tatsächlich die Signalweiterleitung durch c-Met hemmt, habe ich 
die Expression von Kandidaten untersucht, die für solche Funktionen in Frage 
kommen. Ein Protein Screen hat das „intercellular adhesion molecule-1“ (ICAM-
1) als solches identifiziert. ICAM-1 ist ein Zelladhäsionsmolekül, das an ERM 
Proteine und an HA bindet. Blockierungsexperimente mit Antikörpern und siRNA 
Experimente haben bestätigt, dass ICAM-1 für die Aktivierung von c-Met und 
Signalweiterleitung nach der Stimulierung durch den Liganden HGF notwendig 
ist. 
Diese Ergebnisse zeigen einen neuen Co-Rezeptor für c-Met und implizieren 
eine mögliche Substitution für CD44 Funktionen in CD44 Knockout Mäusen. 
ii 
Intercellular Adhesion Molecule 1 (ICAM-1), a Novel 
Co-receptor for c-Met 
ABSTRACT 
In several transformed and normal cells the transmembrane protein CD44v6 is 
required for activation and downstream signalling of the hepatocyte growth factor 
(HGF) receptor c-Met. However in situations where CD44 is not expressed i.e. in 
hepatocytes or in CD44 knockout mice does the c-Met receptor collaborate with 
other transmembrane partners for its activation and signal transduction? The idea 
that such molecules exist that can overtake CD44 functions came from CD44 
knock out mice, which display an essentially normal phenotype.  
In order to find an alternative co-receptor for c-Met I analysed c-Met activation in 
cells devoid of CD44v6, the human hepatocellular carcinoma cell line HepG2. In 
these cells I checked for features of CD44v6 required for c-Met activity (i) 
modulation of c-Met signal transduction via the actin cytoskeleton linker, the 
ezrin/radixin/moesin (ERM) proteins (ii) repression of c-Met activation through the 
extracellular matrix component, hyaluronic acid (HA) and (iii) complex formation 
with c-Met. 
Since I confirmed in competition and siRNA experiments the requirement of ERM 
proteins in c-Met downstream signalling and furthermore that HA can indeed 
repress signalling from c-Met in the HepG2 cells, I looked for the expression of 
candidate molecules that could mediate these functions. Such a protein screen 
identified the intercellular adhesion molecule-1 (ICAM-1). ICAM-1 is a cell 
adhesion molecule implicated in binding to ERM proteins and HA. Antibody 
blocking and siRNA experiments confirmed that ICAM-1 is required for the 
activation of c-Met and signal transduction upon ligand stimulation by HGF. 
These results demonstrate a novel co-receptor for c-Met and suggests that it 
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Physiological and pathological behaviour of cells requires their ability to sense 
their environment and transmit or process what they sense, producing tightly 
controlled responses such as proliferation or migration. The complex 
environment outside the mammalian cell comprises the extracellular matrix 
(ECM), which is made up of various different proteins such as collagen, 
fibronectin and glycosaminoglycans (GAGs). In addition there are a multitude of 
other macromolecules such as growth factors, cytokines or chemoattractants, 
which co-exist in the ECM. Cells sense the components of the environment by 
expressing a number of transmembrane molecules that are able to bind directly 
to the ECM components, the other external factors or molecules on other cells. 
Upon binding stable or transient complexes are formed and may elicit a number 
of downstream mitogenic or morphogenic consequences. One group of such 
molecules are the cellular adhesion molecules (CAMs). 
CAMs embrace a large group of structurally different membrane molecules 
primarily involved in cell-cell or cell-ECM interactions. These interactions are 
important in maintaining tissue integrity and in processes requiring migration 
such as lymphocyte homing or metastasis. The major groups include selectins, 
integrins, the immunoglobulin (Ig) superfamily e.g. intercellular adhesion 
molecules (ICAMs), and proteoglycans such as the syndecan family or the CD44 
family.  
A different class of membrane molecules involved in sensing the extracellular 
environment are the growth factor (GF) receptors. They are essential molecules 
that bind their cognate ligands in the extracellular milieu resulting in a varied 
collection of growth, proliferative or differentiation responses. A subset of growth 
factor receptors are the receptor tyrosine kinases (RTK), which have the ability to 
add a phosphate group to specific tyrosine residues on a protein or substrate. 
There are 58 RTKs in humans, which make up about 20 subfamilies and are 
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expressed in a cell or tissue specific manner primarily involved in cell growth 
(ExPASy web database) e.g. the Epidermal growth factor receptor family 
(EGFR), Vascular endothelial growth factor receptor family (VEGFR), Fibroblast 
growth factor receptor family (FGFR), the nerve growth factor (NGF) receptor 
family Trk, or the hepatocyte growth factor/scatter factor (HGF/SF) receptor 
family c-Met. 
Interestingly a number of CAMs and GF receptors can co-operate in response to 
external stimuli thus expanding the cellular repertoire. Of interest in this study is 
the interplay between the CAMs, CD44 and the GF receptor c-Met. 
CD44 
CD44 is a key adhesion molecule as well as a molecular modulator of 
extracellular cues expressed in a vast array of tissues. It was discovered in 1980 
on leukocytes and cells of the haematopoietic system (Dalchau et al. 1980), then 
as a hyaluronate receptor (Lacy and Underhill 1987), a glycoprotein of Mr 85,000 
(gp85) (Underhill et al. 1987), a phagocyte glycoprotein-1 (Pgp-1) (Mackay et al. 
1988) and a Hermes antigen (Picker et al. 1989). Molecular sequencing 
established that these proteins were all one designated CD44 (Naor et al. 1997). 
Gene structure 
CD44 actually comprises of a family of type I transmembrane glycoproteins. The 
diversity of protein products is due primarily to differential alternative splicing of 





Figure 1. Schematic representation of the CD44 gene. Exons 6-15 are subject to alternative 
splicing and are also known as the variant (v) exons v1-v10. 
 
A single gene found on chromosome 11 in humans (Forsberg et al. 1989) and 
chromosome 2 in mice (Colombatti et al. 1982) encodes the CD44 proteins. The 
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gene, which spans approximately 50kb is organised into 20 exons (Fig. 1) 
(Screaton et al. 1992). Exons 1-17 encode the extracellular portion of which 10 
exons (exons 6-15) are subject to alternative splicing and thus generates the 
CD44 variant (v) isoforms designated exons v1-v10 (Screaton et al. 1992; 
Screaton et al. 1993). Exon 18 encodes the transmembrane domain and the first 
three amino acids of the cytoplasmic domain (Screaton et al. 1992). The 
cytoplasmic domain encoded by exons 19 and 20 is also subject to alternative 
splicing. Exclusion of exon 19 generates a long tail of around 70 amino acids. 
Exon 19 inclusion generates a short tail of 3 amino acids due to an alternative 












Figure 2. A simplified representation of CD44 isoforms protein structure. The smaller CD44s 
isoform (left) and a CD44 isoform containing all the variants are depicted (right). The N-terminal 
globular domain is subjected to extensive N-linked (light blue balls) and O-linked (yellow balls) 
glycosylation. The stem region is identified by the GAG chondroitin sulphate modification (dark 
blue balls). Inclusion of the variant exons increases the stem region and introduces the GAG 
heparan sulphate modification at exon v3 (green ball).  
 
The smallest and most abundant isoform is the CD44 standard or haematopoietic 
(CD44s or CD44H respectively) form of 361 amino acids in human (or 363 amino 
acids in mouse) (Naor et al. 1997), where all the variant exons are excluded (Fig. 
2 left). Inclusion of all the variant exons expands the protein by 381 amino acids 
in humans. The largest isoform in humans contains variant exons v2-v10 and is 
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found in keratinocytes (Bloor et al. 2001). In humans exon v1 contains a stop 
codon and is not expressed (Screaton et al. 1993). 
Extracellular portion 
The first 5 exons encode the “5’ constant” amino-terminal (N-terminal) domain 
(∼180 amino acids), thus being common in all isoforms and are highly conserved 
amongst mammalian species (∼85%). In humans, the N-terminal domain 
contains 6 cysteine residues involved in forming 3 disulphide bonds, which are 
thought to be determinants in forming a globular structure (Fig.2) (Goldstein et al. 
1989). This domain is responsible for binding to the extracellular matrix 
component hyaluronic acid (HA), which has been mapped to exons 2 and 3 
(Thorne et al. 2004). This region of ∼100 amino acids is known as the Link-
homology module due to its resemblance to the HA binding domains of cartilage 
link protein, aggrecan and tumour necrosis factor stimulated gene 6 (TSG-6) 
(Kohda et al. 1996; Bajorath et al. 1998). The N-terminal domain also contains 
sites for post-translational modifications. Five conserved sites of the consensus 
sequence Asn-X-Ser/Thr for N-glycosylation are found and are thought to 
modulate HA binding of CD44 in human and mouse cells (Fig 2) (Bartolazzi et al. 
1996; English et al. 1998).  
Membrane proximal region 
Exons 4 and 5 together with exons 16 and 17 (3’ constant region) encode the 
membrane proximal stem region in the CD44s isoform. It is in this region that the 
insertion site for additional sequences of the variant isoforms is contained thus 
allowing for an enlarged membrane proximal portion (Tolg et al. 1993). In 
addition this region is subjected to extensive post-translational modifications. 
Indeed, the predicted size of the CD44s core protein has an apparent Mw of 37-
38 kDa (Goldstein et al. 1989; Stamenkovic et al. 1989). Utilisation of the 6 N- 
and 7 O-linked glycosylation sites in humans (5 and 10 in mouse respectively) 
doubles the molecular weight to 80-95 kDa (Zhou et al. 1989; Lokeshwar and 
Bourguignon 1991). There are in addition four Ser-Gly motifs in human CD44 
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(three in mouse) that can be modified by GAGs (Goldstein et al. 1989; 
Stamenkovic et al. 1989). CD44s is modified with keratan sulphate and 
chondroitin sulphate (CS) (Fig.2) and is involved in modulating binding to ECM 
components in metastatic cells (Henke et al. 1996; Takahashi et al. 1996). 
Variant isoforms 
Inclusion of the variant exons v1-v10 expands the number of potential N- and O- 
linked glycosylation sites particularly at exons v2 and v8-v10 (Naor et al. 1997). 
Variant isoforms can also expand the GAG binding capabilities of CD44 by 
altering the specificity of ligand binding i.e. v6 and v7 containing isoforms bind 
directly to multiple GAGs like CS or heparin (Sleeman et al. 1997). The CD44v3 
isoform has a consensus Ser-Gly-X-Gly motif for the modification of the GAG 
heparan sulphate (HS) (Bennett et al. 1995), which enables the binding of 
heparin-binding growth factors to CD44. 
Soluble CD44 
Soluble fragments of the extracellular portion of CD44 (sCD44) are detectable in 
culture supernatants and in normal sera from healthy and diseased patients 
(Ristamaki et al. 1994). sCD44 isoforms are shed from the membrane and may 
compete with cell surface CD44 for ligand binding. For example, sCD44 has 
been used to interfere with CD44-HA interactions inhibiting tumour cell 
proliferation (Yu et al. 1997). The major mechanism of CD44 release from cells 
involves proteolytic cleavage by metalloproteases and serine proteases (Bazil 
and Strominger 1994; Kajita et al. 2001). 
Transmembrane and Cytoplasmic domains 
The transmembrane domain contains Cys residues, which undergo fatty acid 
addition or palmitoylation. This modification may play a role in CD44-ankyrin 
binding (Bourguignon et al. 1991) and with signal transduction since it interferes 
with CD3 mediated signalling in lymphocytes (Guo et al. 1994). This domain may 
also be important in CD44 clustering as a small proportion of CD44s formed 
dimers after stimulation with phorbol myristate acetate (PMA) and the Cys 
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residues may help to form stable aggregates with implications for HA binding (Liu 
and Sy 1996). 
The cytoplasmic tail of CD44 contains a number of serine residues that are 
subject to phosphorylation e.g. Ser325 phosphorylation may be important in HA 
mediated cell migration (Peck and Isacke 1998). The cytoplasmic tail also 
contains binding sites for molecules that associate with the actin cytoskeleton 
e.g. ezrin (Thorne et al. 2004). The best characterised cytoskeleton mediators 
are the ezrin/radixin/moesin (ERM) proteins. They are members of the band 4.1 
superfamily, which have a filamentous (F)-actin binding site in their C-terminus. 
The association between CD44 and ezrin is modulated by phosphorylation of 
CD44 Ser291 by protein kinase C (PKC) in vivo (Legg et al. 2002). Importantly, 
the neurofibromatosis 2 (NF2) tumour suppressor protein merlin (moesin-ezrin-
radixin-like) can also bind to the cytoplasmic tail of CD44 and is important in 
modulating growth with the ERM proteins (Morrison et al. 2001). Interestingly, a 
recent study demonstrated the neural Wiskott-Aldrich syndrome (N-WASP) 
protein can complex with CD44 linking it to the actin cytoskeleton via the actin 
related protein 2/3 Arp2/3 binding complex contributing to F-actin formation and 
tumour cell migration (Bourguignon et al. 2007). 
In addition, numerous other proteins can form complexes at the cytoplasmic tail 
of CD44 such as the Rho-family of GTPases and members of the Src family of 
non-receptor tyrosine kinases potentially linking CD44 to downstream signalling 
pathways although whether their interaction is direct or functionally relevant is 
unclear (Ponta et al. 2003; Thorne et al. 2004). 
Expression and Biological functions of CD44 proteins 
The CD44 family of proteins are widely and dynamically expressed primarily on 
the epithelium of various tissues during embryogenesis, in the adult and in 
tumours. CD44s is the most ubiquitously expressed of the isoforms and can be 
found in most tissues of the adult organism with a more restricted pattern in the 
embryo (Wheatley et al. 1993; Terpe et al. 1994). The CD44 variant isoforms in 
contrast, have a highly limited and specific expression pattern in the embryo and 
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adult, mainly localised in regions of active cell growth such as the basal layers of 
stratified epithelium or the apical ectodermal ridge (AER) (Alho and Underhill 
1989; Wheatley et al. 1993; Mackay et al. 1994; Terpe et al. 1994; Ruiz et al. 
1995).  
Physiological functions 
Numerous antibody interference studies against all or specific CD44 isoforms 
have contributed to elucidating their functionally diverse physiological roles in 
activities such as adhesion, proliferation and migration. More specifically CD44 
proteins are involved in processes including haematopoiesis (Miyake et al. 1990) 
and lymphocyte activation and homing (Huet et al. 1989; Shimizu et al. 1989; 
Jalkanen et al. 1990). In the haematopoietic system, strong expression of CD44s 
is observed and studies indicate that the expression of CD44 isoforms are 
dynamically regulated as is the case during T-lymphocyte activation (Naor et al. 
1997; Ponta et al. 1998). CD44 isoforms are thus important in the maturation as 
well as the homing of haematopoietic progenitor cells (Khaldoyanidi et al. 1996; 
Khaldoyanidi et al. 1997). Unsurprisingly then, CD44 plays a role in inflammation 
and has been implicated in several inflammatory and autoimmune diseases (see 
pathological functions below) (Foster et al. 1998; Pure and Cuff 2001). 
CD44 isoforms (particularly variant) are strongly expressed in the skin. RT-PCR 
analysis demonstrated that keratinocytes predominantly express CD44 
molecules containing all the variant isoforms (CD44v2-v10 in humans) (Hudson 
et al. 1995; Bloor et al. 2001). In keratinocytes CD44-mediated proliferation and 
adhesion plays a role in wound healing, tissue integrity and maintaining skin 
elasticity (Hudson et al. 1995; Kaya et al. 1997). 
Development 
During embryogenesis, CD44 isoforms are highly expressed in some tissues, 
which also correlate with HA-mediated morphogenesis and organogenesis e.g. 
the heart or somites (Fenderson et al. 1993; Wheatley et al. 1993). Studies using 
antibody interference against CD44s and CD44v6 in pregnant rats demonstrated 
a role for CD44 isoforms during ontogeny (Zoller et al. 1997). For example anti-
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CD44s caused delays in delivery and frequent intrauterine abortions. Anti-
CD44v6 hampered development until day 16-18 of gestation (E16-18). In 
contrast, the large CD44v3-v10 isoform is expressed in the instructive epithelial 
layer of the developing limb, the AER. This isoform with its heparan-sulphate 
modification is necessary for growth factor presentation of fibroblast growth 
factor-8 (FGF-8) to the underlying mesenchymal cells of the developing limb, 
conveying a proliferative signal (Sherman et al. 1998). This CD44 variant isoform 
is required for correct outgrowth of limbs. 
Pathological functions 
CD44 isoforms are involved in a number of autoimmune diseases. Blocking 
antibodies against CD44 could reduce collagen induce rheumatoid arthritis in 
mouse models (Zeidler et al. 1995). Expression of CD44 on immune cells was 
involved in endothelial cell damage and interleukin 2 (IL-2) induced vascular leak 
syndrome (Rafi-Janajreh et al. 1999). CD44 variant containing isoforms have 
been implicated in inflammatory disease such as inflammatory bowel disease 
where their expression leads to increased survival of effector lymphocytes and a 
persistence of inflammation (Wittig et al. 2000). 
A vast amount of data unequivocally illustrates the role of CD44 in tumour 
formation and metastasis. For instance, one of the first studies that investigated 
CD44 isoforms in cancer demonstrated that expression of specific variant 
isoforms was linked to lymphatic spread of tumour cells i.e. CD44v6 containing 
isoforms were able to confer metastatic potential to non-metastatic rat carcinoma 
cells (Gunthert et al. 1991; Rudy et al. 1993). Interestingly, mis-regulation of 
CD44 does not appear to be due to mutations in the gene itself but to factors that 
can influence the expression of the CD44 gene and which may also be 
implicated in carcinogenesis (Ponta et al. 2003). For example there is a 
correlation between growth factor regulated signalling pathways i.e. Ras-mitogen 
activated protein kinase (Ras/MAPK), and modulation of CD44 expression in 
tumour cell lines (Hofmann et al. 1993; Hamada et al. 1998). CD44 isoforms are 
expressed on a number of primary human tumours originating from cells of the 
INTRODUCTION   
 9 
breast, brain, colon and skin (Hart et al. 1991; Dall et al. 1995; Naor et al. 1997; 
Reeder et al. 1998). Expression particularly of CD44 variant isoforms is often 
correlated with poor prognosis due to metastasis i.e. CD44v6 containing isoforms 
expression in colorectal carcinoma (Sleeman et al. 1995 Naor, 1997 #4148; 
Wielenga et al. 1998). In contrast, CD44 is downregulated in neuroblastomas 
and prostate carcinomas (Shtivelman and Bishop 1991; De Marzo et al. 1998), 
which also correlates with poor prognosis. The variant isoforms do not hold the 
monopoly in tumourigenesis e.g. CD44s is associated with growth of mouse 
melanomas (Bartolazzi et al. 1994). Certain isoforms have been reported to shed 
more easily in disease. Elevated levels of sCD44 and sCD44v6 are observed in 
patients with lymphoma (Ristamaki et al. 1994) and sCD44v6-10, 7-10 and 8-10 
may play a role in determining rate of tumour formation (Bartolazzi et al. 1995). 
Interestingly, the metastasis conferring CD44v6 containing isoforms are required 
for T and B lymphocyte activation (Arch et al. 1992). Clearly, the adhesive, 
migratory, proliferative and anti-apoptotic functions of CD44 offer an advantage 
to neoplastic development. 
CD44 binding partners and molecular mechanisms 
CD44 and Hyaluronic Acid 
Hyaluronic Acid (HA) is a high molecular weight polysaccharide of the ECM 
consisting of repeats of the disaccharide unit D-glucuronic acid and N-acetyl-D-
glucosamine component. HA acts as a space filling component of the ECM and 
is particularly enriched in pericellular matrices surrounding migrating and 
proliferating cells during embryogenesis, tissue repair as well as tumourigenesis 
(Pure and Cuff 2001). In addition HA is abundant in connective tissue such as 
the skin dermis or the lungs (Naor et al. 1997). Functionally HA is important in 
hydration of tissues, organisation of the ECM and through interactions with its 
principle cell surface receptor CD44, influences cell behaviour. Subsequently, 
CD44-HA interactions are important in many cell-ECM mediated processes 
including lymphocyte rolling, in the inflammatory response and tumourigenesis. 
Studies concerning the binding of CD44 isoforms to HA are conflicting however, 
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the cell type as well as the post-translational modifications of the CD44 isoforms 
needs to be considered in modulating CD44-HA interactions (Naor et al. 1997). 
Interestingly, CD44 is involved in mediating the internalisation of HA in several of 
cell types including macrophages (Thorne et al. 2004). A number of studies have 
demonstrated that this uptake is physiologically relevant. The absence of CD44 
by knock out studies, lead to an abnormal accumulation of HA in tissues with 
consequences in wound healing and aggravated immune responses (Kaya et al. 
1997; Teder et al. 2002; Nedvetzki et al. 2004). 
CD44 as a membrane platform 
CD44 interacts with a number of growth factors and matrix metalloproteinases 
(MMP) functioning as a specialised docking area in the control of cellular 
processes such as growth (Ponta et al. 2003). In mammary carcinoma and 
melanoma cells CD44 localises MMP-9 to cell surfaces, which is necessary for 
degradation of collagen IV, correlates with tumour cell invasiveness (Yu and 
Stamenkovic 1999), and it is important for tumour angiogenesis in vivo (Yu and 
Stamenkovic 2000). Furthermore, MMP-9 can cleave latent transforming growth 
factor β (TGF-β) leading to its activation and tissue remodelling (Yu and 
Stamenkovic 2000). In another study CD44HSPG (v3 containing isoform) recruits 
MMP-7 and heparin-binding epidermal growth factor precursor (pro-HBEGF) to 
the epithelial cell surfaces of tissues including the postpartum uterus and 
lactating mammary glands (Yu et al. 2002). This enables MMP-7, probably 
through proteolytic cleavage, to process the precursor to mature HBEGF, which 
can bind and activate its receptor ErbB4, one consequence of which is cell 
survival. The assembly of the surface complex is important in tissue remodelling 
of the female reproductive organs and disruption in localisation of the 
components i.e. MMP-7 has implications in the regulation of apoptosis. Recently, 
CD44 was shown to interact with a RhoA guanine nucleotide exchange factor 
(RhoGEF) the leukemia-associated RhoGEF (LARG) (Bourguignon et al. 2006). 
LARG acts as a linker between CD44 and the epidermal growth factor receptor 
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(EGFR) leading to HA dependent activation of EGFR and tumour growth in head 
and neck squamous cell carcinoma. 
CD44 mediated growth factor presentation 
The HBEGF-ErbB4 interaction also illustrates the ability of CD44 isoforms to 
mediate interactions between GFs and their receptors, in a GF presentation 
mechanism. The heparan-sulphate side chain of CD44v3 containing isoforms is 
able to bind a number of heparin-binding growth factors such as the HBEGF, 
FGF and HGF. During limb development, CD44HSPG presents FGF on one cell 
type to its high affinity receptor on another (Sherman et al. 1998). In Namalwa 
Burkitt's lymphoma cells transfection of the CD44HSPG sequesters HGF and this 
is necessary for activation of the c-Met receptor and downstream signalling (van 
der Voort et al. 1999). 
CD44 as a co-receptor 
Mechanistically, GF presentation is not the only way CD44 isoforms assist cell 
surface receptors, CD44 isoforms can also act as co-receptors. CD44 can 
interact with surface receptors like the ErbB family. The interaction between 
CD44 and ErbB2 is important for their activation in ovarian carcinoma cell growth 
and migration (Bourguignon et al. 1997; Bourguignon et al. 2007). CD44s may 
catalyse heterodimerisation between ErbB2 and ErbB3 in response to their 
ligand neuregulin in Schwann cell differentiation and growth of the peripheral 
nervous system (Ponta et al. 2003). In contrast to the GF presentation 
mechanism, a CD44v6 isoforms can act as a co-receptor for c-Met in different 
cell lines (discussed below) (Orian-Rousseau et al. 2002).  
CD44 and ERM proteins 
The ERM proteins are important modulators between membrane proteins and 
the actin cytoskeleton. CD44 can influence downstream signalling pathways in 
cells through binding to ERM proteins. In human kidney cells, the CD44-ERM 
interaction is required for signalling from the c-Met receptor to the extracellular 
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signal-related kinase1/2 (ERK1/2) (Orian-Rousseau et al. 2002). In a CD44v6 
absent cell line introduction of constitutively active ezrin fused with tailless 
CD44v6 promoted HGF/SF dependent signalling (Orian-Rousseau et al. 2007). 
Conversely, down-regulation of ezrin by small interfering RNA (siRNA) abrogated 
HGF/SF downstream signalling. In addition, signalling from the c-Met receptor 
modulated by CD44v6-containing isoforms can be disrupted by overexpression 
of a CD44v6tailess-ezrin fusion protein mutated in the actin binding domain 
(Orian-Rousseau et al. 2007). Collectively these data demonstrate that ezrin and 
F-actin are necessary to propagate HGF dependent signalling. 
CD44 knockout studies 
CD44 total knockout mice 
CD44 null mice have been generated by targeted deletion of exons 2 and 3, 4 
and 5, and by an in-frame disruption of the leader peptide (Schmits et al. 1997; 
Protin et al. 1999; Yu et al. 2002). Surprisingly, in all reported cases homozygous 
mutant mice were born viable, fertile, and with the normal Mendelian ratio. 
Despite the expression pattern of CD44 proteins in the embryo and their role in 
limb outgrowth, CD44 null mice exhibited no developmental defects. CD44 null 
mice grew without abnormalities in size, cellularity or tissue architecture (Schmits 
et al. 1997). The homozygous mutant mice, although phenotypically normal, did 
however display some mild abnormalities. Altered tissue distribution of myeloid 
progenitor cells between the bone marrow and the spleen suggested that CD44 
is involved in egress of these cells from the bone marrow (Schmits et al. 1997). 
CD44 is also implicated in lymphocyte recirculation in vivo as CD44 null 
lymphocytes exhibit impaired homing to the thymus and peripheral lymph nodes 
(Protin et al. 1999). Pregnant CD44 null mice displayed postpartum defects; 
uterine involution was accelerated and impairment in maintaining lactation, 
highlighting the importance of CD44 in female reproductive organ tissue 
remodelling (Yu et al. 2002).  
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Further, CD44 null mice displayed more pronounced phenotypes when 
challenged: 1) CD44 null mice display exaggerated granuloma response when 
challenged with heat-killed Cryotsporidium parvum, which reflects minor defects 
in the co-ordination of this immune response (Schmits et al. 1997). 2) Following 
induced lung injury, CD44 null mice die due to unresolved inflammatory response 
i.e. impaired clearance of apoptotic neutrophils, persistent accumulation of 
hyaluronan fragments at the site of tissue injury, and impaired activation of 
transforming growth factor-beta1 (TGFβ-1) (Teder et al. 2002). 3) When crossed 
into a Fas null background, CD44 null mice exhibited an increased autoimmune 
lymphoproliferative disease, which correlated with increased resistance of T-cells 
to activation-induced cell death (Do et al. 2003). 
CD44 conditional knockout 
An alternative approach to gain further insight into the biological role of CD44 
was the creation of transgenic mice expressing an antisense CD44 cDNA (Kaya 
et al. 1997). In an antisense orientation, the entire mouse CD44s cDNA was 
cloned downstream of the bovine keratin-5 gene promoter. The result was a 
tissue specific loss of CD44 expression, which leads to a complete loss of CD44 
in all layers of the epidermis and outer root sheath of hair follicles. Newborn mice 
did not display any skin abnormalities. However phenotypical deficits became 
more apparent with age. Loss of keratinocyte CD44 was accompanied by 
morphological alterations in the basal keratinocytes and loss of HA in 
interkeratinocyte spaces with accumulation of HA in the superficial dermis. This 
was reflected in the abnormal skin elasticity of the transgenic mice. In addition, 
defective keratinocyte proliferation in response to mitogen and growth factors 
was observed. This together with reduced skin elasticity contributed to delays in 
wound healing, which in comparison to control animals was delayed by 4-7 days. 
Delays in hair re-growth by 5 days could also be attributed to reduced 
keratinocyte proliferation in the hair bulb. That CD44 is important for skin 
proliferation and the correct hyaluronate homeostasis is clearly demonstrated by 
the severity of the skin phenotype. 
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Compensation of CD44 
The defects in the conditional knock out mice coupled with the relatively normal 
nature of the CD44 total knockout mice indicates that a compensatory 
mechanism takes place whereby other genes may be differentially regulated to 
fulfil the functional role of CD44. That this compensation must take place during 
early embryogenesis is further substantiated by the apparent strong phenotypic 
discrepancies between the total and antisense knockout mice. Abrogation of 
CD44 expression by the antisense cDNA occurs at a later time point during 
embryogenesis (E11.5), i.e. a stage well after early limb outgrowth (Sherman et 
al. 1998). 
In fact two independent studies have implicated different compensatory 
mechanisms for the loss of CD44. Studies of limb bud development in the CD44 
null mice indicated that the proliferative mesenchymal cells increased their 
sensitivity to FGF (Wainwright 1998). Since in the wild type situation heparan-
sulphate modified CD44 is required for FGF presentation, in the CD44 null mice 
these cells may express or utilise another HSPG. 
In contrast, another group reported that the receptor for hyaluronan-mediated 
motility (RHAMM) compensates for CD44 in inflamed CD44 null mice (Nedvetzki 
et al. 2004). Using a collagen-induced arthritis challenge they demonstrated that 
joint inflammation in CD44 null mice was more severe than in the wild type 
situation. This was due to an enhanced ability of RHAMM to support the 
inflammatory cascade. The mechanism of compensation is not due to up-
regulation of RHAMM, but rather that the loss of CD44 causes an accumulation 
of HA thus augmenting signalling through the ready available RHAMM. 
 
These data demonstrate that the diversity of CD44’s molecular actions appears 
to require different substitute mechanisms. 
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c-Met the receptor for hepatocyte growth factor 
(HGF) 
c-Met is a receptor tyrosine kinase (RTK) that when bound by its ligand 
hepatocyte growth factor/scatter factor (HGF/SF) is involved in a number of 
cellular responses including proliferation, migration, invasion and differentiation. 
c-Met was originally discovered as a proto-oncogene that mapped to 
chromosome 7 in humans (a region associated with disease formation) (Cooper 
et al. 1984a; Cooper et al. 1984b). In contrast HGF and SF were independently 
identified as a mitogenic factor (HGF) in primary rat hepatocytes and a factor 
involved in loss of cell contacts (SF) and migration in normal epithelial cells 
respectively (Nakamura et al. 1984; Stoker et al. 1987). Three independent 
studies demonstrated that both are the same molecule (Bottaro et al. 1991; 
Naldini et al. 1991b; Naldini et al. 1991c). 
Structural features of HGF/SF and c-Met 
HGF/SF is a heterodimeric protein that is homologous to the plasmin precursor 
plasminogen (Nakamura et al. 1989). A precursor pro-HGF/SF single chain 
protein of 83kDa is encoded in a single open reading frame. After proteolytic 
processing, the mature active form consists of two subunits linked by a 
disulphide bond, a 69kDa α subunit and a 39kDa β subunit (Nakamura et al. 
1987; Nakamura et al. 1989). The α subunit contains an N-terminal domain and 
four kringle (K1-K4) domains, which are required for c-Met binding with the K1, 
K2 and K4 domains being sufficient for activation of the receptor (Hartmann et al. 
1992; Holmes et al. 2007). In addition the β subunit contains a serine protease 
domain, which provides additional binding and is necessary for the full-scale 
activation of all signalling events including mitogenic activity (Lokker et al. 1992; 
Okigaki et al. 1992). 
c-Met is the prototypic member of a family of RTKs, which include Ron and Sea 
(Huff et al. 1993; Ronsin et al. 1993). Like its ligand, c-Met is a heterodimer of 2 
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disulphide-linked subunits. Biosynthetic studies showed that c-Met exists as a 
glycosylated precursor protein of 190kDa, which undergoes proteolytic cleavage 
to form 50kDa α subunit and 145kDa β subunit. (Giordano et al. 1989a; Giordano 
et al. 1989b). The short α subunit is extracellular and contains a semaphorin-like 
sema domain. The β subunit comprises the rest of the ectodomain, the 
transmembrane domain and the cytoplasmic domain. The extracellular portion of 
the β subunit also contains a sema domain, as well as a cysteine rich plexin, 
semaphorin and integrin (PSI) domain and four Ig (Ig1-4) domains. Finally a 
juxtamembrane region and kinase domain makes up the cytoplasmic tail region.  
Expression and biological functions of c-Met and 
HGF/SF 
Expression analysis determined that c-Met is a broadly distributed protein, 
primarily expressed on epithelial cells (Chan et al. 1988; Di Renzo et al. 1991). It 
is found in a number of different organs of the developing and adult organism. 
For example strong expression of c-Met is found in such organs as the liver and 
the kidney (Andermarcher et al. 1996). In addition, c-Met is expressed in a 
number of tumour cells many of which are epithelial in origin (Di Renzo et al. 
1991). The expression pattern of HGF/SF similarly follows that of its receptor 
however it is secreted by mesenchymal cells (Zarnegar and DeFrances 1993) 
normally in close vicinity to receptor expressing cells (Sonnenberg et al. 1993) 
signifying that HGF/SF stimulation is mainly paracrine.  
Physiological functions 
HGF/SF-c-Met signalling is important for proliferation of various cell types 
including hepatocytes (Machide et al. 2006), keratinocytes (Kan et al. 1991), 
endothelial cells (Rubin et al. 1991), melanocytes (Halaban et al. 1993) and renal 
cells (Ishibashi et al. 1992). It also stimulates the loss of cell junctions and the 
gain of motility (scattering) (Gherardi et al. 1989). Most strikingly it stimulates 
movements into artificial basement membrane (invasion) (Singh-Kaw et al. 
1995). The HGF/SF-c-Met pathway induces differentiation responses in cells 
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known as branching morphogenesis, relevant for the development of the kidney, 
liver and mammary glands (Birchmeier et al. 1993; Bowes et al. 1999). Thus this 
process is involved in organogenesis and organ regeneration in adult tissues. 
Branching morphogenesis is a highly complex process, which also requires cells 
to proliferate, migrate, polarise, communicate with cells and the ECM, and invade 
the surrounding matrix, although it is not exactly understood how the HGF/SF-c-
Met pathway modulates some of these events (Zhang and Vande Woude 2003). 
However organisation of cell proliferation and migration by the HGF/SF-c-Met 
pathway has been shown to be important in wound healing and the formation of 
new blood vessels (angiogenesis) in endothelial cells (Bussolino et al. 1992). 
Development 
The HGF/SF-c-Met signalling pathway is essential for proper development, which 
is highly dependent on the epithelial-mesenchymal expression between receptor 
and ligand. The generation of HGF/SF null or c-Met null mice resulted in 
embryonic lethality (E14.5) due to defects in the development of the placenta 
(Bladt et al. 1995; Uehara et al. 1995). Placental development requires 
stimulation of placental epithelial cells (trophoblasts) by HGF/SF producing 
mesenchymal cells (from the allantois). In addition abnormal cell morphology and 
number in the developing liver was observed (Schmidt et al. 1995) leading to 
reduced liver size. The loss of the HGF/SF-c-Met signalling pathway also 
severely affects the development of skeletal muscle as migration of the myogenic 
precursor cells is lost (Bladt et al. 1995). Interestingly, there is a correlation with 
the high expression of HGF/SF and c-Met during embryogenesis and their 
essential functions, in tissues like the placenta or the liver. 
Cancer 
The evidence for the involvement of the HGF/SF-c-Met pathway in cancer is 
compelling. Firstly, c-Met was originally identified as an oncogene where its 
transmembrane and C-terminal portion was fused with the N-terminus of 
translocated promoter region (TPR) called TPR-Met (Park et al. 1986), which is 
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ligand independent, constitutively active and highly transforming (Rodrigues and 
Park 1993). Secondly, targeted expression of HGF/SF to various tissues in 
transgenic mice lead to the formation of several types of tumours (Takayama et 
al. 1997) illustrating in vivo transforming capability. Thirdly, introduction of c-Met 
and HGF (or mutant c-Met) into cells conferred the properties of motility, 
invasiveness, and tumourgenicity to transformed cells (Jeffers et al. 1997; Jeffers 
et al. 1998; Christensen et al. 2005). Finally, alterations in c-Met or HGF/SF are 
implicated in human cancers i.e. mutations in c-Met, overexpression of c-Met 
and/or HGF/SF, and autocrine signalling from this pathway has contributed to 
transformation and metastasis of numerous tissue types including breast, colon, 
lung and pancreas (Maulik et al. 2002). Specifically, HGF/SF overexpression is 
correlated with breast cancer liver metastases (Eichbaum et al. 2006). In the 
instance of TPR-Met, although initially observed in chemically transformed cells, 
it has been detected in patients with gastric carcinomas (Yu et al. 2000). Since 
the HGF/SF-c-Met pathway is responsible for a multitude of cellular events it is 
not surprising to find them aberrantly organised in numerous cancers. 
HGF/SF-c-Met signalling 
HGF/SF binds c-Met at the α chain and the first 212 amino acids of the β chain 
(Bottaro et al. 1991; Gherardi et al. 2003). This combined region called the sema 
domain of c-Met is required for receptor dimerisation, which triggers 
autophosphorylation of tyrosine residues in the cytoplasmic domain (Naldini et al. 
1991a; Gherardi et al. 2006). Phosphorylation of tyrosine residues (Tyr1234 and 
1235) in the kinase domain are critical for receptor activation whilst 
phosphorylation of Tyr 1349 and 1356 in a cluster of amino acids C-terminal of 
the kinase domain is essential for activation of the multi-substrate docking site, 
which allows binding of proteins involved in downstream signalling form c-Met 
(Ferracini et al. 1991; Longati et al. 1994; Zhu et al. 1994; Pelicci et al. 1995). 
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c-Met effectors 
A multitude of proteins are recruited to the activated c-Met C-terminus and 
include the multi-domain adaptor proteins growth factor receptor bound protein 2 
(Grb2) (Ponzetto et al. 1994) Src-homology 2 (SH2) containing protein (Shc) 
(Pelicci et al. 1995) and Grb2-associated binding protein 1 (Gab1) (Weidner et al. 
1996), and other signal transducers such as the p85 subunit of 
phosphotidylinsitol 3-kinase (PI3K) (Graziani et al. 1991), the Ras guanine 
nucleotide exchange factor son-of-sevenless (SOS) (Graziani et al. 1993) and 
Src kinase (Ponzetto et al. 1994). In many cases substrate interaction with c-Met 
is mediated through SH2 domains, whilst SH3 domains can bind to the other 
signal transducers (Birchmeier et al. 2003; Bolanos-Garcia 2005). c-Met 
activates a series of signalling pathways including the Ras-MAPK or PI3K 
pathway mainly through two major adaptor molecules Gab1 and Grb2 (Zhang 
and Vande Woude 2003). 
 
Gab1 is a large multi-adaptor protein that is essential to c-Met signalling. The 
Gab1 knockout mice display almost identical phenotypes to the HGF/SF and c-
Met null mice e.g. impairment in migration of muscle precursors, reduced liver 
size and placental defects (Sachs et al. 2000). Gab1 binds directly to c-Met 
through its unique c-Met binding domain (MBD) or indirectly via Grb2 (Weidner et 
al. 1996) and recruits a number of SH2 containing proteins i.e. PI3K, 
phospholipase Cγ (PLCγ), SH2 containing protein tyrosine phosphatase 2 
(SHP2) and the Crk family of adaptors (Gao and Vande Woude 2005). Signalling 
mediated via Gab1 requires multifaceted co-ordination of these downstream 
effectors in physiological processes such as scattering and branching 
morphogenesis, and cell survival (Gual et al. 2000; Maroun et al. 2000; Fan et al. 
2001; Zhang and Vande Woude 2003). A number of studies have also 
demonstrated the requirement of Gab1 and its effectors in cell transformation 
(Fixman et al. 1997; Mood et al. 2006; Watanabe et al. 2006). 
The Grb2 adaptor protein contains an SH2 domain, which interacts with Tyr1356 
of cytoplasmic c-Met (Ponzetto et al. 1994). Grb2 interacts with SOS through its 
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SH3 domains and links c-Met to the Ras-MAPK pathway since SOS activates 
Ras (Furge et al. 2000). c-Met signalling mediated by Grb2 is important in 
processes such as proliferation, migration, invasion and branching 
morphogenesis (Zhu et al. 1994; Maina et al. 1996; Maina et al. 2001). In 
addition Grb2 binding to c-Met is implicated in cellular transformation (Ponzetto 
et al. 1996). 
In summary, the c-Met signalling pathways are complex. Differential contribution 
of the signalling pathways regulate signalling responses i.e. PI3K and Ras-MAPK 
are both required in scattering and tubulogenesis in MDCK cells (Khwaja et al. 
1998). These data signify that the HGF/SF-c-Met signalling pathway are 
important for neoplastic as well as normal cellular processes including growth 
and invasion (Bardelli and Comoglio 1997). 
 
c-Met signalling partners 
c-Met functions may be influenced by input signals that complement its activity in 
a tissue-specific manner. For instance c-Met can bind to cell surface proteins, 
which aid in activation or signalling. These interactions may be required in 
regulating different threshold levels of signal output, which are thought to be 
important in modulating the different responses from c-Met. 
c-Met and α6β4 integrin 
α6β4 integrin is a cell surface adhesion protein usually involved in cell-ECM 
interactions and typically involved in adhesive structures. It also contributes to 
neoplastic invasion. α6β4 integrin was found to interact with c-Met and act as a 
signal amplifier in invasive growth of carcinoma cells (Trusolino et al. 2001). 
HGF/SF stimulated activation of c-Met leads to phosphorylation of the β4 
cytoplasmic domain, which recruits SHC and PI3K leading to activation of 
Ras/MAPK pathway. 
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c-Met and Plexin B1 
c-Met can form a complex with Plexin B1, a c-Met related protein (28% homology 
to c-Met) and the receptor for semaphorin 4D (Sema 4D) (Giordano et al. 2002). 
Semaphorins are important for control of axon guidance. Interestingly the 
association with c-Met allows Sema 4D induced (through binding to Plexin B1) 
tyrosine phosphorylation of c-Met and elicits invasion and branching 
morphogenesis. In addition Sema 4D and HGF can co-operatively induce 
invasive growth. Plexin B1 thus acts as a c-Met primer in normal and tumour 
invasion and expands the ligand repertoire. 
CD44, a dedicated co-receptor in HGF/SF induced 
activation and downstream signalling of c-Met 
The observations that CD44 and c-Met are both expressed in diverse tissues and 
up-regulated in number of cancers prompted investigations into a possibly co-
operation between them. A CD44v6 containing isoform and c-Met were found to 
interact in a number of transformed and non-transformed cells (Orian-Rousseau 
et al. 2002). The consequences of the association are two-fold i) the CD44v6 
extracellular domain is required for c-Met activation by organisation of a ternary 
complex between CD44v6, c-Met and HGF/SF. A short three amino acid region 
in CD44v6, RWH in humans, is essential for c-Met activation (Matzke et al. 2005) 
ii) the cytoplasmic tail of the CD44v6 isoform is required for HGF/SF dependent 
activation of the Ras/MAPK pathway. The transmission of signal depends on the 
interaction between CD44 and the ERM proteins and the recruitment of the actin 
cytoskeleton. The assembly of this complex at the membrane is important for 
HGF/SF dependent activation of Ras by its GEF, SOS (Orian-Rousseau et al. 
2007). 
Thus, the interaction between CD44v6 and c-Met at least in several tissues is a 
prerequisite for the receptor activation. 
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AIM 
The principle aim of this thesis is to find proteins that can in the absence of 
CD44v6, act as an alternative co-receptor for the receptor tyrosine kinase c-Met. 
The idea that molecules exist that can take the place of CD44 functions came 
from the discrepancies in CD44 loss of function studies. By investigating cell 
systems where CD44 is not normally expressed or has been removed and 
exploiting the fact that c-Met can utilise co-receptors, I hope to find a molecule 
that may function in a similar fashion to CD44v6 as a co-receptor for c-Met. 
 
MATERIALS AND METHODS   
 23 
MATERIALS AND METHODS 
Materials 
Chemicals: All general chemicals were, unless otherwise stated, supplied by 
Carl Roth GmbH & Co (Karlsruhe, Germany), Merck (Darmstadt, Germany), and 
Sigma Chemie GmbH (Deisenhofen, Germany) and were of the highest purity 
grade. 
Oligonucleotides 
RNA, small interfering RNA, (siRNA) 
Human ICAM-1  20-25nt siRNA (Santa Cruz) 
Human Ezrin  Pool of 3 target-specific 20-25nt siRNAs (Santa Cruz) 
Mouse ICAM-1 20-25nt siRNA (Santa Cruz) 
Control 20-25nt non-targeting siRNA  (Santa Cruz) 
 
Plasmids 
pCI-neo ICAM-1 Gift from Dr. Oli Carpen (Sweden) (Heiska 
et al. 1998) 
pCI-neo vector control Promega 
GST-CD44 cytoplasmic tail Gift from Dr. C. Isacke (Legg and Isacke 
1998) 
GST-CD44 cytoplasmic tail mutated 
in ERM binding region 
Gift from Dr. C. Isacke (Legg and Isacke 
1998) 
GST vector control Gift from Dr. C. Isacke (Legg and Isacke 
1998) 
pGKCD44v6 Gift from Dr J Sleeman 
pGK vector control Gift from Dr. J Sleeman 
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Antibodies 
Antibodies  Isotype Specificity Source 




Detection of CD44 
exonv6 encoding 
epitope from rat 
Purified from 
ascites 
CD44/Pgp-1 Rat IgG1κ 
Detection of all CD44 
isoforms from mouse 
SouthernBiotech 
ERK 1/2 (K-23) Rabbit IgG1 
Human, rat, and 
mouse 
Santa Cruz 
Ezrin (3C12) Mouse IgG1 
Human, monkey, 
cow, rat and mouse 
NeoMarkers 
Hermes 3 Mouse IgG1 
Detection of all CD44 
isoforms from human 
Gift from Sirpa 
Jalkanen, Turku, 
Finnland 
ICAM-1 (CD54) Mouse IgG1 Human R&D systems 
ICAM-1 (G-5) Mouse IgG2a Human Santa Cruz 
ICAM-1 (M-19) Goat IgG Mouse and rat Santa Cruz 
h-Met (C-12) Rabbit IgG1 Human Santa Cruz 
m-Met Mouse IgG2a Mouse and rat Santa Cruz 
Moesin (E-10) Mouse IgM 

















Plakophilin 2a Mouse IgG1 Human 
Transduction 
Laboratories 
Plexin-B1 (H-300) Rabbit IgG Mouse, rat & human Santa Cruz 
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Radixin (C-15) Goat IgG 
Detection of Radixin 
(to a lesser extent 
Ezrin and Moesin) 
from rat, mouse and 
human 
Santa Cruz 
Syndecan-1 (C20) Goat IgG 
Mouse, rat and 
human 
Santa Cruz 
Syndecan-2 (M-140) Rabbit IgG 
mouse, rat and 
human 
Santa Cruz 
Syndecan-4 (H-140) Rabbit IgG 




Secondary antibodies: HRP-Mouse IgG, HRP-rat IgG, HRP-rabbit IgG and HRP-
Goat IgG were purchased from Dako company, Hamburg. 
Isotype control antibodies: Rat IgG2a, Rat IgG2b, Mouse IgG2b were purchased 
from Southern Biotechnology Associates Inc., U.S.A. and Mouse IgG1 from R&D 
systems. 
Peptides 
Mouse CD44 exon v6 A:  ETWFQ NGWQG 
The peptide sequence corresponds to a part of mouse CD44 exon v6 sequence 
Control peptide   HNREQANLNSRTEETI 
Enzymes and growth factors 
Heparinase II  (Sigma) 
pro-HGF  (R&D systems) 
Cell lines and general cell culture media 
Cell culture reagents 
Trypsin, 0.25%    Difco, Detroit  
DMEM    GibcoBRL Life Technologies, Karlsruhe 
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RPMI 1640    GibcoBRL Life Technologies, Karlsruhe 
Foetal calf serum (FCS)  Bio-Whittaker, Belgium 
Penicillin-Streptomycin  Invitrogen 
L-Glutamine    GibcoBRL Life Technologies, Karlsruhe 
 
Cell lines 
Name Description Culture medium 
HT29 
Human colon 
adenocarcinoma cell line 
DMEM, 10% FCS 
HepG2 
Human Hepatocellular 
carcinoma cell line 
DMEM, 10% FCS 
CD44WT or KO 
keratinocytes 
Primary mouse keratinocytes 
isolated from the skin 
epidermis 
4x Low Ca2+ MEM 
(see in keratinocyte 
cell culture below) 
CD44WT or KO 
hepatocytes 
Primary mouse hepatocytes 
isolated from the liver 
DMEM, 10% FCS 
BSp73AS10 (AS10) 
Rat pancreatic carcinoma 
cell line 
RPMI 1640, 10% 
FCS 
AS14 
AS10 cells transfected with 
CD44v4-v7, without 
5G8 epitope (exon 15) 





General Methods: A number of protocols and recipes for common buffers used 
in this project were taken from the laboratory manual of (Maniatis et al. 1989) 
unless otherwise stated. Aqueous solutions were prepared with water purified by 
the Milli-Q plus water purification system (Millipore, Molesheim, Germany). 
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General Cell culture 
Unless otherwise stated, cells were maintained in a humidified (95%) 
atmosphere with 5% CO2 at 37°C. The cell culture medium for each type of cell 
line has previously been described (see Materials, paragraph cell line).  
Cells were frozen in freezing medium (10% DMSO in FCS). The cell suspension 
was transferred into pre-chilled cryo-vial, left on ice for 1 hour and then frozen at 
-80°C. For long-term storage, the frozen cells were transferred into liquid 
nitrogen.  
Frozen cell were thawed fast in a 37°C water-bath, and transferred into a 15ml 
falcon tube containing pre-warmed fresh medium. The cells were spun and 
resuspended in fresh medium and plated in a flask or a Petri dish. 
Murine Epidermal Keratinocytes (MEKs) 
Medium 
Media and media-salts were purchased from Biochrom AG (Berlin, Germany), 
fetal calf serum (FCS) from PAA (Cölbe, Germany) and penicillin-streptomycin 
and phosphate buffered saline without Ca2+ or Mg2+(PBS) Gibco (Germany) 
4xMEM “high Ca2+”  
(Minimal essential medium with 4 times the concentration of amino acids and 
vitamins) 
Hanks solution (10x) 40ml 
MEM Vitamin (100x) 16ml 
MEM amino acids (50x) 32ml 
MEM non-essential (100x) 16ml 
L-Glutamine (200 mM) 5ml 
Biocarbonate (7.5%) 16ml 
Penicillin/Streptomycin (100x) 5ml 
Sterile distilled water to 500ml 
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The pH of the solution was adjusted with 1M NaOH to pH 7.2. After sterile 
filtration (Millipore Steritop, 0.22µm) the medium was supplemented with 10% 
FCS. 
 
4xMEM “low Ca2+” 
Hanks solution (1x without Ca2+,Mg2+ with phenol red) 400ml 
MEM Vitamin (100x) 16ml 
MEM amino acids (50x) 32ml 
MEM non-essential (100x) 16ml 
L-Glutamine (200 mM) 5ml 
Biocarbonate (7.5%) 16ml 
Penicillin/Streptomycin (100x) 5ml 
MgCl2 (20 g/l) 5ml 
Phenol red 1ml 
 
The pH of the solution was adjusted with 1M NaOH to pH 7.2. After sterile 
filtration the medium was supplemented with 10% chelexed FCS (10ml normal 
FCS and 40ml chelexed FCS) and the calcium concentration adjusted to 
between 0.06-0.08mM using sterile CaCl2. 
Chelexed FCS was prepared by addition of 15g chelex-100 resin (Sigma) per 
500ml FCS and stirred for 1.5 hours at 4°C followed by sterile filtration. 
To starve cells, low Ca2+ MEM supplemented with 0.5% normal FCS and CaCl2 
(0.06mM) was used. 
 
Coating culture dishes with collagen type IV 
Collagen type IV (Santa Cruz Biotechnology) stock solution was thawed for 
several hours on ice then diluted to the appropriate concentration using cold 
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sterile 0.05M HCl. Cellstar™ (Greiner Bio One, Germany) tissue culture dishes 
were coated with between 1-10µg/ml of collagen IV for 1-2 hours at room 
temperature. Dishes were rinsed twice with PBS containing 1% penicillin-
streptomycin, replaced in original packaging, sealed and stored at 4°C until 
required. 
Murine Epidermal Keratinocyte culture 
1-2 day old mice pups (B6,CD44-/- (Schmits et al. 1997)) or (C57Bl/6J wild type) 
were sacrificed by decapitation, washed with 70% ethanol, the limbs and tail 
amputated and the trunk skin removed. The skins were rinsed three times in PBS 
containing 1% penicillin-streptomycin and flattened with the dermal side down on 
tissue culture dishes. The skins were then floated on a 2.4U/ml solution of 
Dispase (Gibco) in PBS (ensuring the liquid did not flow onto the top epidermal 
side) overnight at 4°C. 
The next morning the dispase solution was aspirated; the epidermal layer gently 
peeled away from the dermis, rinsed in PBS and floated outspread in dishes 
containing high Ca2+ MEM (approximately 1.5ml per skin layer). The pooled 
epidermal layers were then cut into smaller pieces and transferred with the 
medium into a sterile glass beaker. The epidermal pieces were stirred at low to 
intermediate speed for 30 min at room temperature. 
The mixture containing disaggregated cells and tissue clumps was poured 
through a sterile cell strainer 70µm (BD Biosciences) (10 skins per cell strainer) 
into a 50ml falcon tube (Greiner Bio One, Germany). The epidermal cells were 
centrifuged at 1000 rpm for 10 min, seeded at 50% cell density in high Ca2+ MEM 
on collagen IV coated plates and placed in a 35°C, 5% CO2 incubator. After 6 
hours the medium was aspirated, cells gently washed once with PBS and low 
Ca2+ MEM gently added. The medium was changed after 24 hours and again 2-3 
days later. Keratinocyte cell growth was monitored between culture days 2-5. 
Experiments were normally performed in this time. 
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Liver cell culture 
Mice pups were sacrificed as described above in keratinocyte culture. Livers 
were dissected and rinsed in PBS (1x) and sequentially incubated for 5 min in 
solution A (EBSS without Ca2+/Mg2+, 0.5mM EGTA), 5 min in solution B (EBSS 
with Ca2+/Mg2+, 10mM HEPES pH 7.4) and 5 min in solution C (EBSS with 
Ca2+/Mg2+, 10mM HEPES pH 7.4, 0.3mg/ml Collagenase type I). Livers were 
washed with PBS (1x) and the cells dispersed by pipetting up and down several 
times with a glass pipette. The cells were then spun down by centrifugation 
seeded in DMEM containing 10% FCS in a plastic dish. The medium was 
changed with washing every day to remove haematopoietic cells. Once a pure 
hepatocyte culture was obtained, medium was changed every 2 days. 
Amaxa Transfections  
Cells were cultivated to 70-80% confluency before transfection according to the 
manufacturers instructions. On the day of transfection cells were trypsinised, 
centrifuged and all traces of medium removed. Cells were resuspended in the 
appropriate room temperature NucloefectorTM solution, 1x106 cell/100µl for a 6-
well plate and 3x106 cells/100µl for a 10cm plate. 100µl of the cell suspension 
was then mixed separately with each oligonucleotide to be transfected in sterile 
eppendorf tubes and transferred to Amaxa cuvettes. Electroporation was carried 
out with the corresponding program for each cell type. Immediately after 
transfection, pre-warmed medium was added to cells (500µl) in the cuvettes then 
the cells were transferred to plates containing pre-warmed medium. 
HA pre-treatment 
High molecular weight HA (Helon Mw: 4-5x103kDa, Pharmacia&Upjohn) 
(400µg/ml) was added to cells and incubated for 5 min at 37°C, then aspirated 
prior to HGF addition.  
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Peptide treatment 
Peptides (100ng/ml) were added to cells and incubated for 5 min at 37°C, then 
aspirated prior to HGF addition. 
Heparinase II treatment 
Heparinase II (6U/ml) was added to cells and incubated for 3 hrs, then aspirated 
prior to HGF addition 
Blocking antibody treatment 
Human anti-ICAM-1 antibody or IgG1 control (20µg/ml) were added to cells and 
incubated for 1 hr at 37°C, then aspirated prior to HGF addition 
HGF induction, chemical cross-linking 
3x106 cells were seeded in 10cm plates, serum starved for 24 hours, and finally 
induced with HGF (50ng/ml) at 37°C for 5 min. After washing the cells 2 times 
with PBS 1x, protein cross-linking in living cells was performed in 3ml PBS 1x 
containing 3mg DTSSP at room temperature for 30 min. The reaction was 
quenched using 40µl/ml of 20mM Tris-HCl pH 7.4.  
The cells were then washed with ice-cold PBS 1x, lysed with either co-
immunoprecipitation lysis buffer (25mM HEPES pH 7.4, 100mM NaCl, 5mM 
MgCl2, 1mM EGTA, 10% glycerol, 1.25% CHAPS, containing protease inhibitors 
(10µg/ml Aprotinin and Leupeptin, 1mM PMSF, 10mM NaF and 2mM Na3VO4) or 
immunoprecipitation lysis buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 1% Triton 
X-100). 
Cell lysate preparation 
In order to analyse protein expression by western blot, cells were washed with 
PBS 1x and lysed in 2x laemmli sample buffer (160mM Tris-HCl pH 6.8, 4% 
SDS, 16% glycerol, 0.1M DTT, 0.01% bromophenol blue). DNA was sheared 
through a 26-guage needle. The cell lysate was incubated 5 min at 95°C for 
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protein denaturation, and centrifuge for 1 min at 10 000 rpm before loading on 
SDS-PAGE gel.  
Immunoprecipitation 
Cells grown in 10cm plates were washed twice with ice-cold PBS 1x and lysed in 
1ml of lysis buffer containing protease inhibitors as listed in the HGF induction 
section (above). After an incubation of 30 min on ice, lysed cells were scraped 
and pooled in a 1.5 ml eppendorf. The lysate was cleared by a centrifugation of 
15 min at 13000g, at 4°C. The supernatant was transferred to a fresh tube. 5µg 
of antibody per ml of cell lysate was added and the mixture was rotated overnight 
at 4°C. 40µl of 50% beads slurry (previously equilibrated in lysis buffer) was 
added to the sample, and was rotated for 1 to 3 hours at 4°C. Immuno-
complexes were recovered by centrifugation and washed 3 times for 1 min, with 
cold lysis buffer. Supernatant was removed, beads were then resuspended in 
50µl of laemmli sample buffer and boiled at 95°C for 5 min. After spinning down 
the beads by centrifugation, the supernatant was loaded on a SDS-PAGE gel, or 
stored at -20°C. 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were electrophoretically separated on the basis of size using the method 
of Laemmli (1970). The resolving gel (8.5-10% acrylamide) and the stacking gel 
(5% acrylamide) were cast according to (Maniatis et al. 1989). Samples were run 
into the stacking gel at 100 V, and then run at 150 V during the day or 30 V 
overnight. 
The running buffer contained 30.3 g/l Tris-base, 144g/l Glycine, and 1% SDS. 
Western Blotting 
After proteins were separated by SDS-PAGE, they were electrically transferred 
onto Immobilon membrane (Millipore, type PVDF, pre-soaked in methanol) at 35 
V for at least 6 hrs in Transfer Buffer (25 mM Tris-base, 190 mM Glycine, 20% 
Methanol). Following the completion of the transfer, in order to reduce unspecific 
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binding of the antibodies to the PVDF membrane, the blot was incubated in TBS-
0.2% Tween containing 5% bovine serum albumin (BSA) blocking solution, for 1 
hour at room temperature with shaking. For detection of proteins of interest, the 
membrane was further incubated in TBS-0.2% Tween blocking solution 
containing the appropriate primary antibody (at the manufacturer-recommended 
dilution) for 1 hr at room temperature with shaking. After 3 washes (5 min each at 
room temperature with shaking), the membrane was incubated in blocking 
solution containing a 1:1500 dilution of HPR-conjugated secondary antibody. The 
membrane was then washed 5 times 5 min in TBS-Tween. The detection of 
specific proteins was achieved by enhanced chemiluminescence using ECL 
Western blotting detection reagents (Amersham) ECL hyperfilms (Amersham) 
according to the manufacturer’s instructions.  
To reprobe with another antibody, the blots were stripped with washing buffer 
(0.063M Tris-HCl pH 6.8, 2% SDS, 0.8g DTT) at 50°C for 40 min, and then 
treated again as explained above. 
Silver staining 
After proteins were separated by SDS-PAGE, the gel slab was fixed in 50% 
methanol, 5% acetic acid for 1 hour. It was then washed first with 50% methanol 
for 10 min and second with water for another 10 min to remove remaining acid. 
The gel was sensitised by 1 min incubation in 0.02% sodium thiosulfate, and 
rinsed with 2 changes of distilled water for 1 min each. The gel was then 
submerged in ice-cold 0.1% silver nitrate solution and incubated for 20 min at 
4°C. The gel slab was afterwards rinsed twice with water for 1 min and 
developed in 0.04% carbonate with intensive shaking. Once the developer 
solution turned yellow, it was replaced by fresh a one. It is essential that the 
development be carried out in an absolutely transparent solution. The 
development was achieved when the desired intensity of staining was obtained. 
The developer solution was then discarded and the gel was washed with 5% 
acetic acid.  
Silver stained gels were stored in 1% acetic acid at 4°C. 
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RESULTS 
Hepatocyte growth factor, HGF can activate c-Met and induce 
downstream signalling in a cell line that does not express CD44 
molecules 
It has been extensively shown in a number of transformed and non-transformed 
cell lines that CD44v6-containing isoforms are required for the HGF/SF induced 
activation of the c-Met receptor and signalling via the Ras/MAPK signalling 
pathway (Orian-Rousseau et al. 2002; Orian-Rousseau et al. 2007). However, in 
several cases where c-Met can be activated by its ligand, CD44 isoforms are not 
expressed e.g. in hepatocytes and hepatanomas (Seelentag et al. 1995; 
Washington et al. 1997). To investigate the molecular interactions and activity of 
c-Met in the absence of CD44v6 I looked at the human hepatocellular carcinoma 
cell line HepG2. As expected, the HepG2 cells express the c-Met protein but no 
CD44 protein (Fig 3A). I used the HT-29 colon carcinoma cells, which have been 
shown to express both the CD44 isoforms including CD44v6 (Reeder et al. 1998) 
and c-Met (Orian-Rousseau et al. 2002) as a reference for their expression and 
c-Met activity (Fig 3). 
Although the two cell lines do not derive from the same tissue, I needed a control 
system where I knew that c-Met utilised CD44 as a co-receptor. This was 
previously shown using antibodies against the v6-specific isoform of CD44, which 
in the HT-29 cells could block HGF induced activation of the c-Met receptor along 
with phosphorylation of ERK1/2 a downstream target of c-Met (Orian-Rousseau 
et al. 2002) and Fig. 3B. 
Next I checked the activation status of c-Met upon stimulation with its ligand HGF 
in the HepG2 cells. Exponentially growing cells were serum starved for 48 hrs, 
stimulated with HGF and cell supernatants treated with an α-c-Met antibody (Ab). 
Immunoprecipitates and untreated lysates were examined for c-Met and ERK 
phosphorylation on western blots respectively. Fig 3B demonstrates that upon 
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ligand stimulation the c-Met receptor is phosphorylated in the HepG2 cells (upper 
left panel, right lane) and this leads to a subsequent phosphorylation of ERK 
(lower left panel, right lane). The corresponding activation status is depicted in 
the HT-29 cells (right panel). I concluded that the HepG2 cells were a suitable 
cell system to search for a new co-receptor for c-Met. 
 










Figure 3. c-Met is activated by it’s ligand HGF and can signal downstream to ERK in the CD44 
negative carcinoma cell line HepG2. A, Western blot analysis of total cell lysates from HepG2 and 
HT-29 cells using an α-pan-CD44 Ab to detect CD44 expression (upper panel) or a human α-c-
Met Ab for c-Met (lower panel). B, c-Met and ERK phosphorylation in HepG2 and HT-29 cells. 
Logarithmically growing HepG2 and HT-29 cells were serum starved for 48 hrs then either left 
untreated or induced for 5 min with HGF (50ng/ml). After cell lysis, immunoprecipitation was 
performed on cell supernatants with an α-c-Met Ab as described in “Materials and Methods”. 
Immunoprecipitates were analysed on western blots, following SDS-PAGE separation (8.5%), 
using α-phospho-tyrosine Ab (α-pTyr) (first row) and α-c-Met Ab (second row). Untreated cell 
lysates were probed for ERK phosphorylation using a α-p42/44MAPK Ab (third row) and α-ERK 
(fourth row). c-Met and ERK are phosphorylated upon HGF stimulation in both cell lines. 
 
Comparative Co-IP screen for c-Met interacting partners 
Previous studies in the HT-29 cells demonstrated that only upon stimulation with 
HGF could CD44v6 interact with c-Met, forming a multimeric complex between 
the three proteins (Orian-Rousseau et al. 2002). Might a similar interaction occur 
between c-Met and a cell surface molecule in the HepG2 cells? I attempted an 
unbiased approach to find such molecules whereby I compared c-Met 
immunoprecipitates in the HepG2 cells versus the HT-29 cells and observed 
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potential differences in the protein expression or interaction pattern. Cells were 
induced with HGF, treated with the chemical cross-linker dithiobis-
sulfosuccinimidylpropionate (DTSSP) to stabilise cell surface complexes, lysed 
and immunoprecipitated. c-Met precipitates were resolved on SDS-PAGE gels 
and proteins associated with c-Met were visualised by silver staining. Western 
blot analysis confirmed that c-Met was efficiently immunoprecipitated from cell 
lysates (Fig 4, inset). I detected a protein band of approximately 70kDa in the c-
Met precipitate of the HepG2 cells that was not observable in the precipitate of 
the HT-29 cells (Fig 4). Protein sequencing of the band by Maldi-Tof revealed 







Figure 4. A 70kDa protein is associated with c-Met upon HGF stimulation in the HepG2 cells but 
not the HT-29 cells. Logarithmically growing cells were serum starved for 24-48 hrs. After HGF 
induction cells were crossed-linked with DTSSP for 30 min, lysed and immunoprecipitated with α-
c-Met Ab. Following SDS-PAGE separation, immunoprecipitates were analysed on the silver 
stained SDS-PAGE gels (see Materials and Methods). Bands of interest were excised from the 
gel and sent analysed by Maldi-Tof protein sequencing. The arrow indicates the 70kDa protein 
band in the HGF stimulated HepG2 cells. Aliquots of the c-Met immunoprecipitates were loaded 
on a second gel and probed for c-Met pull down efficiency by western blot (inset). 
 
Plakophilin 2 is a member of the armadillo protein family, which are characterised 
by a series of motifs known as the arm-repeats, and whose members include 
protein p120, plakoglobin, β-catenin and its sub-family members plakophilin 1 
and 3 (Mertens et al. 1996; Bonne et al. 1998; Chen et al. 2002). The 
plakophilins are primarily localised to the juxtamembrane plaque of desmosomal 
junctions of simple and complex epithelia and the nucleus (Chen et al. 2002; 
Grossmann et al. 2004; Hatzfeld 2007). 
An interaction between c-Met and plakophilin 2, had not previously been 
described and although plakophilin 2 is not a transmembrane protein, its dual-
cellular localisation has led some groups to speculate that it may be involved in 
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the co-ordination of intercellular junctions and growth control (Chen et al. 2002; 
Hatzfeld 2007) My observation that it is differentially expressed between the two 
cell lines raised some intriguing possibilities towards a potential use in signalling 
from c-Met. To confirm the results I observed in the silver stain, I specifically 
looked for plakophilin 2 in co-immunoprecipitates of c-Met in both cell lines. 
Western blot analysis indicated that plakophilin 2 is expressed in both cell lines. 
Unexpectedly and contrary to the silver stain, plakophilin 2 was found to 








Figure 5. Plakophilin 2 associates with c-Met in HepG2 and HT-29 cells. Non-stimulated and 
HGF induced cells were treated with the chemical cross-linker DTSSP as previous. Following 
lysis, immunoprecipitation with c-Met Ab was performed. Cell samples were probed for the 
presence of c-Met and plakophilin 2 in the precipitates on western blots.  
 
Plakophilin does not as first observed differentially interact with c-Met in the cell 
lines. It’s interaction with c-Met seems to be independent of activation of the 
receptor (Fig 5). Ultimately it seems more plausible that a protein interaction 
between plakophilin 2 and c-Met may be involved in a crosstalk between 
receptors and junctional proteins and have nothing to do with the co-receptor 
function I was looking for. 
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Since c-Met in the absence of CD44v6 is activated and can signal in the Hep G2 
cells, I asked if potential membrane proteins could function in a similar fashion to 
CD44v6 by examining some functions that may, in the HT-29 cells, be mediated 
by CD44 ((Orian-Rousseau et al. 2002) and Orian-Rousseau unpl.) 









Figure 6. Pre-treatment of HepG2 cells with hyaluronic acid (HA) inhibits c-Met signalling. Serum-
starved HepG2 cells were pre-treated with 400µg/ml of HA for 5 min, washed, and then induced 
for 5 min with HGF (50ng/ml). Cell lysates were resolved by SDS-PAGE (8.5%) and ERK 
phosphorylation was determined on a western blot using α-p44/42 MAPK Ab. ERK 
phosphorylation is reduced after cells are pre-treated with HA (lane 2 compared to lane 3). 
 
CD44 is the principle receptor for the ECM protein, HA (Entwistle et al. 1996). 
HA-mediated processes like cell migration and cell adhesion require interactions 
with CD44 i.e. during inflammation infiltrating leukocytes adhere to the ECM. HA 
can also modulate growth through its interaction with CD44. It has been shown in 
several cell lines that pre-treatment of logarithmically growing cells with HA 
negatively influences their growth by induction of a molecular switch in proteins 
complexed at the cytoplasmic tail of CD44 (Morrison et al. 2001). In this “growth 
inhibitory” mode CD44 recruits the ERM-related protein merlin to its cytoplasmic 
tail, which results in its dephosphorylation and induction of its growth suppressive 
function (Morrison et al. 2001). In addition HA can affect GF dependent activation 
of ERK in the HT-29 cells (V. Orian-Rousseau in preparation). I investigated the 
influence of HA treatment on HGF dependent signalling in the HepG2 cells. Cells 
were pre-treated with HA and then stimulated with HGF to activate the c-Met 
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receptor. Compared to HA untreated cells, pre-treatment of cells with HA lead to 
a reduction in HGF dependent ERK phosphorylation (Fig 6, lane 3). This 
suggests that a HA binding protein on the HepG2 cells is involved in mediating c-
Met signalling. 
An ERM binding molecule and ERM proteins are involved in c-
Met signalling in HepG2 cells 
The ERM family of proteins are known to associate to the plasma membrane via 
membrane partners like CD44 and are important for modulating membrane traffic 
and in maintaining cell shape (Louvet-Vallee 2000). The ERM proteins also play 
a major role in c-Met signalling (Orian-Rousseau et al. 2007). In several cell 
lines, where CD44v6-containing isoforms were able to propagate HGF 
dependent signalling to ERK, transfection of the CD44v6-containing isoform 
minus the cytoplasmic tail abolished this signalling (Orian-Rousseau et al. 2002; 
Orian-Rousseau et al. 2007). In addition, a CD44v6-constituitively active ezrin 
fusion protein was able to convey HGF induced downstream signalling to ERK in 
CD44v6 negative rat carcinoma cells Bsp73AS (Orian-Rousseau et al. 2007). 
Conversely, a GST-fused CD44 cytoplasmic tail but not one mutated in the ERM 
binding region could successfully abrogate HGF-dependent signalling to ERK in 
the human kidney carcinoma cell line 293 (Orian-Rousseau et al. 2002). These 
data suggest that c-Met downstream signalling to ERK requires the cytoplasmic 
tail of CD44v6 and ERM proteins in various cells (Orian-Rousseau et al. 2002; 
Orian-Rousseau et al. 2007). 
In cells where CD44 is absent, another ERM binding molecule may take its 
place. To test this notion, I asked if in the HepG2 cells the soluble cytoplasmic 
tail of CD44 sequestering of ERM molecules could interfere with HGF dependent 
activation of ERK. HepG2 cells were transfected by electroporation with either 
the soluble tail of CD44 or the tail with a mutation in the ERM binding domain. 
Compared to the control vector (Fig 7, lane 2), HGF induced ERK 
phosphorylation in cells transfected with the CD44 tail was reduced (lane 4). 
However in cells transfected with an ERM binding mutant tail, ERK 
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phosphorylation was not affected (lane 6). This result implicates ERM-binding 
protein involvement in downstream transmission of c-Met signals in the HepG2 
cells. Accordingly, the ERM proteins seem to be connected in these signalling 









Figure 7. A cytoplasmic portion of CD44 sequesters ERM proteins and affects c-Met signalling in 
HepG2 cells. HepG2 cells were transiently transfected with a GST-CD44 cytoplasmic tail fusion 
construct, one mutated in the ERM binding region, or an empty vector (cont) by Amaxa 
electroporation. 24 hrs later cells were serum-starved for 24 hrs and then induced for 5 min with 
HGF (50ng/ml) at 37°C, subsequently ERK phosphorylation was determined by western blot 
analysis. 
 
To further investigate the relevance of the ERM proteins in c-Met signalling I 
performed another independent experiment. I first determined which of the ERM 
proteins are expressed in the HepG2 cells. Western blot analysis of total cell 
lysates showed that ezrin was the most abundantly expressed of the ERM 
proteins in the HepG2 cells (Fig 8A). Recently, ezrin has been shown to be 
important for c-Met signal transduction in 293 cell and HGF induced scattering in 
the HT-29 cells (Orian-Rousseau et al. 2007). I looked at the effect of down-
regulating ezrin protein expression on ERK phosphorylation in the HepG2 cells. 
siRNA oligonucleotides against ezrin were transfected by electroporation into 
cells and the c-Met signalling as determined by ERK-phosphorylation observed. 
Compared to a scrambled oligonucleotide, the siRNA against ezrin successfully 
reduced ezrin protein expression. In addition this reduction negatively affected 
HGF dependent ERK-phosphorylation. Taken together these data indicate that 
ERM proteins and specifically ezrin, through binding to plasma membrane 
molecules are necessary for c-Met downstream signalling. 
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Figure 8. c-Met signalling is inhibited by down-regulation of the ERM protein ezrin. A Expression 
analysis of ERM proteins. Equal amounts of HepG2 total cell lysate was probed for ERM protein 
expression on western blots. Ezrin and not radixin or moesin is predominantly expressed. B 
Down-regulation of ezrin by siRNA. HepG2 cells were transfected by Amaxa electroporation with 
siRNA against ezrin (300pmol) or a scrambled oligonucleotide (cont). The following day cells 
were serum-starved for 24 hrs then induced with HGF as previous. Cell lysates were assayed for 
total ezrin expression and phosphorylation of ERK. Ezrin reduction leads to a decrease in ERK 
phosphorylation. 
 
Since HA pre-treatment negatively affects c-Met signalling and ERM binding 
proteins and ezrin appear to be involved in c-Met signalling in the HepG2 cells. I 
wondered whether a membrane protein with such functions might act as a co-
receptor, substituting for CD44v6. 
Protein screen of cell lysates reveal a cellular adhesion molecule 
is distinctively expressed in the HepG2 cells compared to the 
HT-29 cells  
I screened whole cell lysates of the HepG2 and HT-29 cells to evaluate the 
expression patterns of membrane proteins. It has previously been demonstrated 
that Plexin B1 and α6β4 can independently act as co-receptors for c-Met 
(Trusolino et al. 2001; Giordano et al. 2002). c-Met was found to associate and 
could be activated by Semaphorin 4D, the ligand of Plexin B1 in liver progenitor 
cells (Giordano et al. 2002). In contrast, α6β4 association with c-Met enhances 
the receptor’s signalling potential via the Ras/MAPK pathway in mammary 
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carcinoma cells (Trusolino et al. 2001). I observed no difference in expression of 
Plexin B1 in the two cell lines and less expression of α6β4 integrin (represented 














Figure 9. Different membrane proteins expression pattern in the HepG2 and HT-29 cells. 
Logarithmically growing cells were lysed and equal amounts of total cell lysates from the HepG2 
and HT-29 cells were separated on SDS-PAGE. Lysates were screened for expression of the 
different membrane proteins by western blot analysis. 
 
Since HGF is a heparin-binding GF and CD44HSPG isoforms have been 
implicated in presenting GF to their receptors including HGF and c-Met (van der 
Voort et al. 1999) I decided to look at other families of HSPGs. The Syndecans 
are a family of four proteins, Syndecan 1-4 whose similarities to CD44 also 
include binding to ERM proteins (Granes et al. 2000). Syndecan-1 was not 
expressed in the HepG2 cells whereas syndecan 2 and 4 were expressed in both 
cell lines albeit slightly less in the HepG2 cells in the case of the latter. Another 
important class of surface molecules that I tested were the intercellular adhesion 
molecules, ICAMs. The ICAMs are also a family of proteins consisting of ICAM 1-
5, involved in leukocyte migration (Yang et al. 2004). Of the detectable proteins, 
only ICAM-1 showed a higher expression in the HepG2 cells versus the HT-29 
(Fig 9, bottom row). 
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ICAM-1 is a plausible candidate because functionally it is similar to CD44. Both 
proteins are cellular adhesion molecules also expressed on leukocytes and it is 
therefore not surprising that they are involved in inflammatory cell trafficking 
(Jalkanen et al. 1990; Hallahan and Virudachalam 1997). Interestingly ICAM-1 is 
also a HA binding molecule (McCourt et al. 1994; Entwistle et al. 1996) and has 
been reported to associate with ERM proteins (Heiska et al. 1998), placing it in a 









Figure 10. An ICAM-1 Ab reduces HGF dependent ERK phosphorylation in HepG2 cells. 
Logarithmically growing cells were serum starved for 48 hrs. Cells were then pre-treated with an 
α-ICAM-1 blocking antibody (20µg/ml) or an isotype-matched control (cont) for 1 hr, washed and 
induced with HGF. c-Met activity was determined by ERK phosphorylation on western blots. 
 
α-ICAM-1 blocking Abs inhibits downstream signalling in a HGF 
dependent manner 
To explore a relationship between ICAM-1 and c-Met in the HepG2 cells, I 
interfered with ICAM-1 on the cell surface by using an ICAM-1 blocking Ab and 
looked at its affect on c-Met activity. Serum starved cells were pre-treated with 
antibody then stimulated with HGF, downstream signalling to ERK was observed. 
Inducible ERK phosphorylation was reduced in cells pre-treated with ICAM-1 Ab 
but not with a control Ab (Fig 10). This indicated that ICAM-1 might have a role in 
c-Met activation or signalling in the HepG2 cells. 
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Abrogation of ICAM-1 expression leads to inhibition of c-Met 
activation and downstream signalling 
In the HepG2 cells ICAM-1 is highly expressed. Would abolishing its expression 
have an affect on c-Met activation? To test this, I transfected cells with siRNA 
against ICAM-1 and evaluated the expression level of the protein on western 
blots. Compared to cells transfected with the control oligonucleotides, the ICAM-
1 siRNA completely and successfully abolished the expression of endogenous 














Figure 11. ICAM-1 is important in c-Met activation and signal transduction to ERK upon 
stimulation with HGF. HepG2 cells were transfected with siRNA against human ICAM-1 
(400pmol) or a scrambled oligonuclotide (cont) by electroporation. Following stimulation with 
HGF, total cell lysates were analysed for ICAM-1 expression and ERK phosphorylation. c-Met 
was immunoprecipitated from cell lysates and analysed for tyrosine phosphorylation on western 
blots 
 
In the same experiment I investigated the amount of c-Met activation and ERK 
phosphorylation under HGF stimulating conditions in the ICAM-1 silenced cells. 
HGF stimulation induces activation of c-Met and ERK phosphorylation in cells 
transfected with control oligonucleotides (Fig 11). However, HGF induced 
phosphorylation of c-Met and ERK are drastically reduced when ICAM-1 protein 
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levels are abolished (Fig 11). These results strongly implicate the requirement of 
ICAM-1 in the activation of the c-Met receptor and subsequent activation of ERK. 
c-Met and ICAM-1 are associated in the HepG2 cells 
The ability of ICAM-1 to assist c-Met is likely to depend on close interactions at 
the cell surface. I therefore investigated if c-Met and ICAM-1 associate by 
performing immunoprecipitation studies. Serum starved HepG2 cells were 
stimulated with HGF followed by chemical cross-linking with DTSSP to stabilise 
extracellular complexes. c-Met and ICAM-1 were immunoprecipitated from cell 
supernatants and the ability of each to co-immunoprecipitate with the other 
observed on western blots. c-Met and ICAM-1 were both successfully pulled out 
from cell supernatants (Fig 12). c-Met associates with ICAM-1 in the absence 
HGF and the association is slightly increased upon HGF stimulation (first row 











Figure 12. ICAM-1 and c-Met associates in the HepG2 cells. Non-stimulated and HGF stimulated 
cells were incubated with the chemical cross-linker DTSSP. After cell lysis, cell supernatants 
were divided and immunoprecipitation with a c-Met or ICAM-1 Ab was performed. Samples were 
probed for the presence of c-Met and ICAM-1 in both precipitates. 
 
ICAM-1 is a co-receptor for c-Met 
If ICAM-1 acts as a co-receptor for c-Met, then it’s introduction into ICAM-1 
negative cells may activate the receptor. The ASs cells are a rat pancreatic 
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carcinoma cell line stably transfected with the CD44 standard isoform. These 
cells express c-Met, however the receptor is not activated upon stimulation with 
its ligand, HGF. Transfection experiments with CD44v6 in these cells lead to 
activation of c-Met as well as signalling to ERK (Orian-Rousseau et al. 2002) and 
Fig 13. This demonstrated that CD44v6 containing isoforms were necessary and 
sufficient for c-Met activity in these cells. I examined if ICAM-1 could similarly 
enable activation of the receptor in these cells. To eliminate any potential 
interference from possible endogenous ICAM-1, I checked for the expression of 
ICAM-1 in these cells. Compared to control murine cells, the ASs cells do not 
express ICAM-1 (Fig 13A). 
 










Figure 13. ICAM-1 can activate c-Met activity and downstream signalling to ERK in ASs cells. A 
The ASs cell do not express ICAM-1. Whole cell lysates from the ASs cells and primary mouse 
keratinocytes were analysed for expression of ICAM-1 by western blots. B Expression of ICAM-1 
or CD44v6 induces HGF dependent ERK phosphorylation. ASs cells were transiently transfected 
with an empty vector or vectors containing ICAM-1 or CD44v6 by electroporation. 24 hrs after 
transfection cells were starved for 36 hrs induced with HGF (10ng/ml) and lysed. Whole cell 
lysates were analysed for expression of ICAM-1, CD44v6 and phosphorylation of ERK by western 
blot.  
 
Next, I transiently transfected a vector expressing ICAM-1 (or CD44v6) by 
electroporation and observed c-Met activity as determined by ERK 
phosphorylation. As expected the ASs cells are not inducible upon HGF 
stimulation also in the presence of the vector control (Fig 13B). However, ERK 
was phosphorylated upon stimulation with HGF only when ICAM-1 (or CD44v6) 
was present (Fig 13B lanes 6 & 8). This activation was HGF dependent as the 
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presence of ICAM-1 (and CD44v6) alone was not able to induce ERK 
phosphorylation (Fig 13B lanes 5 & 7). In the ASs cells ICAM-1 expression is 
necessary to promote c-Met activity. This result clearly shows that ICAM-1 is able 
to function as a co-receptor for c-Met and further substantiates the findings for 
ICAM-1 as a co-receptor for c-Met in the HepG2 cells. 
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DISCUSSION 
The cellular adhesion molecule family of CD44 and the growth factor receptor c-
Met are well established as key mediators of cell growth and differentiation 
during development and in the aberrantly regulated process of tumour 
metastasis. Critically, CD44v6 containing isoforms are required for c-Met 
activation and downstream signalling in several transformed and normal cells 
including primary human keratinocytes. However in situations where CD44 is not 
expressed i.e. in hepatocytes or in CD44 knockout mice, does the c-Met receptor 
collaborate with other transmembrane partners for its activation and signal 
transduction? In this study I provide evidence that in the absence of CD44 the 
intercellular adhesion molecule-1 (ICAM-1) is required for the activation of c-Met 
and signal transduction upon ligand stimulation by HGF. In the same cells an 
ERM binding protein and ezrin are important for c-Met downstream signalling. 
Finally, in these cells a HA binding molecule is involved in modulating affects on 
c-Met activation. 
The relevance of ICAM-1 expression in the HepG2 cells 
ICAM-1 expression has been observed in various tumours including that of the 
liver (Sun et al. 1999; Rosette et al. 2005; Lin et al. 2006). The expression of 
ICAM-1 that I observed in the human hepatocellular carcinoma cell line HepG2 
could be significant in their tumourigenesis. Interestingly and coincident with my 
observation is that ICAM-1 is up-regulated in human hepatocellular carcinomas 
as compared to normal human hepatocytes and this upregulation correlates with 
metastasis (Sun et al. 1999). 
HGF/c-Met may also play a role in the carcinogenesis of liver cells (Luo et al. 
1999; Son et al. 2006; Yang et al. 2007) and since ICAM-1 is important for c-Met 
in the HepG2 cells (Fig. 11) it is tempting to speculate that this interaction may 
play a role in potentiating hepatocellular carcinoma metastasis since both c-Met 
and ICAM-1 can contribute to metastasis. 
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How can ICAM-1 modulate activation of the c-Met receptor? 
In the HepG2 cells c-Met and ICAM-1 can associate independently of HGF 
although this is slightly enhanced upon HGF addition (Fig. 12). A constitutive 
association is in contrast to CD44v6 where an association between c-Met and 
the former seems to be dependent only on the presence of HGF (Orian-
Rousseau et al. 2002). However an inducible association between c-Met and 
ICAM-1 is not per se necessary for c-Met activation. This is substantiated by 
another co-receptor for c-Met plexin B1, which is also constitutively associated 
with the receptor (Giordano et al. 2002). In that case stimulation by the plexin B1 
ligand Sema 4D leads to plexin B1 clustering, which drives oligomerisation and 
activation of c-Met. Clustering of ICAM-1 has been reported and is important for 
its surface localisation (Yang et al. 2006) but it is speculative as to whether this 
could impact c-Met dimerisation and activation. 
 
Heparan sulphate (HS) modification of cell surface proteins like CD44 have 
previously been shown to play a role in binding growth factors like HGF in a GF-
presentation mechanism in Namalwa lymphoma cells (van der Voort et al. 1999). 
Conversely, a HGF mutant that cannot bind to HS can still activate c-Met better 
(Hartmann et al. 1998). Thus heparan sulphation is not always necessary for 
growth factor presentation and this appears to be the case for CD44v6, which is 
not heparan sulphated. We have recently observed that HGF can bind to 
CD44v6 independent of the presence of c-Met. Yet in cells were c-Met is 
expressed but not CD44v6, HGF cannot bind to c-Met (Matzke, A Orian-
Rousseau, V and Ponta H unpl). If this is so then it is plausible that a region in 
CD44v6 is necessary for binding and presentation of HGF to c-Met. Could this 
also be true of ICAM-1? Similarities in the extracellular domains of ICAM-1 and 
CD44 molecules apart from a common HA-binding motif are still to be 
determined. Yet introduction of ICAM-1 or CD44v6 into rat carcinoma cells 
promoted HGF induced activation of c-Met (Fig 13) suggesting that ICAM-1 and 
CD44v6 can modulate an interaction between HGF and its receptor. The 
question of whether ICAM-1 can bind to HGF has not yet been examined but 
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HGF binding studies to the HepG2 cells in the presence and absence of ICAM-1 
will address this point and this will help to understand if ICAM-1, like CD44v6 can 
present HGF to c-Met thus stabilising an interaction between the ligand and 
receptor. Indeed the observation that upon HGF induction the association 
between ICAM-1 and c-Met is slightly enhanced might speak towards a more 
stable surface complex (Fig. 12). 
The ECM may use ICAM-1 to modulate c-Met activity 
It has previously been described that ICAM-1 can bind to HA on synovial 
fibroblasts (Hiramitsu et al. 2006) and contains several near-B(X7)B motifs 
described as the HA binding motif found in proteins like CD44 (Nelson et al. 
1995). An interaction between ICAM-1 and HA could affect c-Met activation by 
inhibiting an interaction between HGF and c-Met, a potential one between HGF 
and ICAM-1 or c-Met and ICAM-1. Concurrent with this idea is the observation 
that ICAM-1 antibody blocking experiments (Fig 10) also negatively affects HGF 
dependent ERK phosphorylation. It is not clear if the antibody could mimic HA 
binding or if it too sterically hinders HGF binding ability. An interpretation of the 
activation status of the c-Met receptor itself would be required to eliminate an 
indirect effect on downstream signalling. 
 
Mechanistically, HA has been proposed to be involved in a reorganisation of 
downstream partners that could affect proliferative responses (Morrison et al. 
2001). Binding of HA to CD44 leads to the recruitment of the active form of the 
ERM related protein merlin, a negative growth regulator. In the CD44 negative 
HepG2 cells, ICAM-1 could potentially bind to merlin, as it has been described to 
interact with ERM proteins (Heiska et al. 1998). Recent data also suggest that 
active merlin may modulate signalling by inhibiting activation of Ras thereby 
affecting downstream targets such as ERK (Morrison et al. 2007). 
A mechanistic modulation of signalling from HA by ICAM-1 like CD44 is plausible 
due to the general trend for ICAM-1 and CD44 to convey similar HA signals. 
ICAM-1 and CD44 have been described to modulate HA mediated inhibition of 
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MMP production in synovial fibroblasts during proinflammatory responses 
(Shimizu et al. 2003; Hiramitsu et al. 2006) and in chondrocytes both CD44 and 
ICAM-1 HA binding contributes to a reduction in anti-Fas induced apoptosis in 
osteoarthritis (Lisignoli et al. 2001). A growth inhibition signal propagated by HA 
in the absence of CD44 can potentially utilise ICAM-1.  
Intracellular cues can be modulated by ICAM-1 in c-Met signal transduction  
The loss of ICAM-1 expression in the HepG2 cells negatively effects c-Met 
activation and subsequently signalling to ERK. Since ICAM-1 can bind to ERM 
proteins (Heiska et al. 1998) like CD44, the potential mechanism for c-Met 
signalling in the HepG2 cells could be mediated via an ICAM-1-ERM interaction. 
This may be possible, as it has recently been demonstrated that a CD44v6-ERM 
interaction is required for HGF-dependent activation of Ras, which strictly 
requires formation of a complex comprising ERM proteins, Grb2, SOS, Ras and 
F-actin (Orian-Rousseau et al. 2007). Interestingly it had been speculated that 
ICAM-1 might transduce signals via adaptor proteins like Grb2 and SOS to ERK 
(Gardiner and D'Souza 1999). 
Attempts to Co-IP endogenous ICAM-1 and ezrin, the predominantly expressed 
ERM protein in the HepG2 cells, were unsuccessful. However it is possible that 
an interaction between them may require mediation of phosphatidylinositol 4,5-
bisphosphate (PIP2). In vitro interaction studies between ICAM-1 and ezrin were 
much more enhanced in the presence of PIP2 (Heiska et al. 1998). Indeed it 
appears that PIP2 binding to ezrin is required for its phosphorylation at Thr567 
(Fievet et al. 2004; Ivetic and Ridley 2004) and enhanced binding to CD44 (Hirao 
et al. 1996). Binding of ICAM-1 to merlin may also be mediated in this way since 
binding is between the N-terminal portion of ezrin and PIP2, and merlin and ezrin 
have 61% homology in this region (Tsukita and Yonemura 1999).  
CD44 candidate substitute molecules in primary mouse cells 
The mild phenotype of CD44 total knock out (KO) mice suggests that the 
organism elicits a mechanism to manage CD44 functions. Such a mechanism of 
compensation for CD44 molecules must take into account molecules that 
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participate in similar functions of CD44, like c-Met activation. The finding that 
ICAM-1 could function as a co-receptor for c-Met in the HepG2 cells lead to the 
question as to whether it could function as a substitute molecule in the same 
capacity in CD44KO mice. Preliminary studies in primary mouse hepatocytes 
from mice using siRNA against mICAM-1 indicated that loss of ICAM-1 correlated 
with a reduction in HGF-dependent ERK phosphorylation in the CD44KO mice, 
which was not observed in the CD44 wild type (WT) mice (Fig.14B) although it is 
expressed in both situations (Fig 14A). What is still not clear is whether in the 
normal situation c-Met utilises CD44 isoforms in these cells (or another 
molecule). During mouse embryogenesis CD44 expression is differentially 
regulated in the liver until day E11.5 (Wheatley et al. 1993) but there are no 
studies on CD44 expression in newborn mice. It will be interesting to see if the 












Figure 14. Loss of ICAM-1 expression affects c-Met activity in CD44 KO primary mouse 
keratinocytes. Hepatocytes were isolated from the livers of CD44WT and KO mice and placed 
into culture at 37°C, 5% CO2. A ICAM-1 is expressed in both the WT and KO mouse hepatocytes 
B siRNA against ICAM-1 inhibits HGF-dependent ERK phosphorylation in the KO but not WT 
hepatocytes. One week after isolation, logarithmically growing cells were transfected with siRNA 
against mICAM-1 (300pmol) or a scrambled oligonucleotide. The cells were serum starved as 
previous and induced with HGF, c-Met activity was observed as determined by ERK 
phosphorylation on western blots. 
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In primary human keratinocytes, pre-treatment of cells with CD44v6 blocking 
antibodies inhibits HGF induced c-Met activation and downstream signalling to 
ERK (Orian-Rousseau et al. 2002). I isolated primary mouse keratinocytes from 
CD44WT and CD44KO mice and could observe that in the CD44WT 














Figure 15. CD44 Expression and requirement of CD44v6 for c-Met activity in primary mouse 
keratinocytes. Primary cells were isolated as described in Materials and Methods. A CD44 
isoforms are expressed in the cell lysates from WT but not KO keratinocytes. B A murine CD44v6 
peptide blocks c-Met activation and subsequent downstream signalling in CD44WT but not 
CD44KO mouse keratinocytes. Logarithmically growing primary cells were serum starved for 24 
hr. Cells were pre-treated with murine or control peptides (100ng/ml) 5 min 37°C, then induced 
with HGF (10ng/ml).  
 
Since no inhibitory v6 anti-mouse antibodies are available, I designed short 
peptides against the corresponding region in mouse v6 that have been shown to 
be important for human v6 for c-Met activation (Matzke et al. 2005). Pre-
treatment of keratinocytes with the murine peptide indeed blocked activation of c-
Met in the CD44WT cells suggesting that CD44v6 acts as a co-receptor for c-Met 
in a manner similar to the human keratinocytes. The same peptide did not, of 
course, block c-Met activation in the CD44KO keratinocytes (Fig. 15B). The 
advantage of this system is that I can make comparisons based solely on the 
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presence or absence of CD44 in relation to c-Met. Importantly, in the CD44KO 
keratinocytes c-Met is still activated and the signal is transduced to ERK (Fig. 
15B). This could mean that c-Met activation may be independent of co-receptor 
molecules, also in other CD44 negative cells or that c-Met utilises other 
accessory proteins. The evidence presented from mine and other studies 
suggest that cell surface receptors like c-Met, FGFR or ErbB form co-operative 
relationships with other surface molecules, which are required for their activation 
and signal transduction (Bourguignon et al. 1997; Wainwright 1998; Orian-
Rousseau et al. 2002) and this may also be the case in the CD44KO 
In the absence of CD44 an organism may cope with its loss by up-regulating or 
activating other molecules, with similar functional properties, ICAM-1 could be 
such a molecule. The keratinocytes from WT and KO mice express ICAM-1 (Fig. 
16). Unfortunately, the primary mouse keratinocytes are highly sensitive and 
difficult to transfect therefore I was unable so far to clarify the relevance for 
ICAM-1 in these cells. Interestingly ICAM-1 is not particularly up-regulated in the 
CD44KO keratinocytes but syndecan-2 is in comparison to the WT keratinocytes 
(Fig 16). Thus syndecan-2, which provides similar functions to CD44 and ICAM-1 







Figure 16. Syndecan-2 and not ICAM-1 is differentially expressed in the CD44KO keratinocytes 
as compared to the CD44WT keratinocytes. Logarithmically growing cells were lysed and 
analysed for protein expression by western blot.  
 
Generally, syndecan-2 belongs to a family of HSPGs (Syndecans 1-4) that like 
CD44 are involved in cell-ECM communication, and have the ability to bind 
growth factors (Beauvais and Rapraeger 2004). Syndecan-1 was demonstrated 
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to bind HGF and promote c-Met signalling in multiple myelomas an apparent 
presentation mechanism that utilised the HS moieties (Derksen et al. 2002). 
The syndecan proteins also exhibit a high degree of conservation in their 
cytoplasmic domain, which includes an ERM protein-binding domain (Beauvais 
and Rapraeger 2004). Studies have also shown that syndecan-2 can directly 
bind to ezrin thus linking syndecan-2 to the actin cytoskeleton and the ability to 
mediate signal transduction in CD44 negative cells (Granes et al. 2000; Granes 









Figure 17. A HSPG can modulate c-Met activation and subsequent signal transduction in KO but 
not WT keratinocytes. Logarithmically growing cells were pre-treated with Heparinase II (6U/ml) 
at 37°C for 3 hrs. Cells were induced with HGF and assayed for ERK activation 
 
Testing a potential role of syndecan-2 in c-Met activation in the CD44KO 
keratinocytes was hindered by their sensitivity to transfection and the lack of 
efficient antibodies against murine syndecan-2. I decided to take an indirect 
approach and examined the potential of a HSPG to affect c-Met activity. 
Keratinocytes from WT and KO mice were pre-treated with Heparinase II to 
remove all HS side chains from surface molecules. Preliminary data suggests 
that a HSPG via a HS moiety on the KO keratinocytes modulates c-Met activity 
(Fig 17). Whether this molecule is syndecan-2 still remains to be determined. 
 
I have described a novel function for ICAM-1 as a co-receptor for c-Met, which is 
independent of any previously known ICAM-1 functions, largely described in 
terms of adhesion to leukocytes. ICAM-1 shares functional similarities like HA or 
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ERM binding capability to another co-receptor for c-Met, CD44v6. Although the 
question of ICAM-1 as a substitute molecule is still unclear the capacity for 
ICAM-1 to act as a co-receptor for c-Met supports the idea that different 
molecules can substitute for CD44 by different mechanisms. 
REFERENCES   
 57 
REFERENCES 
Alho, A.M. and C.B. Underhill. 1989. The hyaluronate receptor is preferentially 
expressed on proliferating epithelial cells. J Cell Biol 108: 1557-65. 
Andermarcher, E., M.A. Surani, and E. Gherardi. 1996. Co-expression of the 
HGF/SF and c-met genes during early mouse embryogenesis precedes 
reciprocal expression in adjacent tissues during organogenesis. Dev 
Genet 18: 254-66. 
Arch, R., K. Wirth, M. Hofmann, H. Ponta, S. Matzku, P. Herrlich, and M. Zoller. 
1992. Participation in normal immune responses of a metastasis-inducing 
splice variant of CD44. Science 257: 682-5. 
Bajorath, J., B. Greenfield, S.B. Munro, A.J. Day, and A. Aruffo. 1998. 
Identification of CD44 residues important for hyaluronan binding and 
delineation of the binding site. J Biol Chem 273: 338-43. 
Bardelli, A. and P.M. Comoglio. 1997. Scatter factor receptors are key players in 
a unique multistep program leading to invasive growth. Ciba Found Symp 
212: 133-44; discussion 144-7. 
Bartolazzi, A., D. Jackson, K. Bennett, A. Aruffo, R. Dickinson, J. Shields, N. 
Whittle, and I. Stamenkovic. 1995. Regulation of growth and dissemination 
of a human lymphoma by CD44 splice variants. J Cell Sci 108 ( Pt 4): 
1723-33. 
Bartolazzi, A., A. Nocks, A. Aruffo, F. Spring, and I. Stamenkovic. 1996. 
Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to 
hyaluronan. J Cell Biol 132: 1199-208. 
Bartolazzi, A., R. Peach, A. Aruffo, and I. Stamenkovic. 1994. Interaction 
between CD44 and hyaluronate is directly implicated in the regulation of 
tumor development. J Exp Med 180: 53-66. 
Bazil, V. and J.L. Strominger. 1994. Metalloprotease and serine protease are 
involved in cleavage of CD43, CD44, and CD16 from stimulated human 
granulocytes. Induction of cleavage of L-selectin via CD16. J Immunol 
152: 1314-22. 
REFERENCES   
 58 
Beauvais, M.D. and A.C. Rapraeger. 2004. Syndecans in tumor cell adhesion 
and signalling. Reprod Biol Endocrinol 2: 1-12. 
Bennett, K.L., D.G. Jackson, J.C. Simon, E. Tanczos, R. Peach, B. Modrell, I. 
Stamenkovic, G. Plowman, and A. Aruffo. 1995. CD44 isoforms containing 
exon V3 are responsible for the presentation of heparin-binding growth 
factor. J Cell Biol 128: 687-98. 
Birchmeier, C., W. Birchmeier, E. Gherardi, and G.F. Vande Woude. 2003. Met, 
metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-25. 
Birchmeier, W., K.M. Weidner, and J. Behrens. 1993. Molecular mechanisms 
leading to loss of differentiation and gain of invasiveness in epithelial cells. 
J Cell Sci Suppl 17: 159-64. 
Bladt, F., D. Riethmacher, S. Isenmann, A. Aguzzi, and C. Birchmeier. 1995. 
Essential role for the c-met receptor in the migration of myogenic 
precursor cells into the limb bud. Nature 376: 768-71. 
Bloor, B.K., M. Jelvagharan, K.N. White, and E.W. Odell. 2001. Characterization 
of CD44 splicing patterns in normal keratinocytes, dysplastic and 
squamous carcinoma cell lines. Int J Oncol 18: 1053-9. 
Bolanos-Garcia, V.M. 2005. MET meet adaptors: functional and structural 
implications in downstream signalling mediated by the Met receptor. Mol 
Cell Biochem 276: 149-57. 
Bonne, S., J. van Hengel, and F. van Roy. 1998. Chromosomal mapping of 
human armadillo genes belonging to the p120(ctn)/plakophilin subfamily. 
Genomics 51: 452-4. 
Bottaro, D.P., J.S. Rubin, D.L. Faletto, A.M. Chan, T.E. Kmiecik, G.F. Vande 
Woude, and S.A. Aaronson. 1991. Identification of the hepatocyte growth 
factor receptor as the c-met proto-oncogene product. Science 251: 802-4. 
Bourguignon, L.Y., E. Gilad, A. Brightman, F. Diedrich, and P. Singleton. 2006. 
Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and 
epidermal growth factor receptor promotes Rho/Ras co-activation, 
phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in 
REFERENCES   
 59 
head and neck squamous cell carcinoma cells. J Biol Chem 281: 14026-
40. 
Bourguignon, L.Y., E.L. Kalomiris, and V.B. Lokeshwar. 1991. Acylation of the 
lymphoma transmembrane glycoprotein, GP85, may be required for 
GP85-ankyrin interaction. J Biol Chem 266: 11761-5. 
Bourguignon, L.Y., K. Peyrollier, E. Gilad, and A. Brightman. 2007. Hyaluronan-
CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) 
promotes actin polymerization and ErbB2 activation leading to beta-
catenin nuclear translocation, transcriptional up-regulation, and cell 
migration in ovarian tumor cells. J Biol Chem 282: 1265-80. 
Bourguignon, L.Y., H. Zhu, A. Chu, N. Iida, L. Zhang, and M.C. Hung. 1997. 
Interaction between the adhesion receptor, CD44, and the oncogene 
product, p185HER2, promotes human ovarian tumor cell activation. J Biol 
Chem 272: 27913-8. 
Bowes, R.C., 3rd, R.T. Lightfoot, B. Van De Water, and J.L. Stevens. 1999. 
Hepatocyte growth factor induces tubulogenesis of primary renal proximal 
tubular epithelial cells. J Cell Physiol 180: 81-90. 
Bussolino, F., M.F. Di Renzo, M. Ziche, E. Bocchietto, M. Olivero, L. Naldini, G. 
Gaudino, L. Tamagnone, A. Coffer, and P.M. Comoglio. 1992. Hepatocyte 
growth factor is a potent angiogenic factor which stimulates endothelial 
cell motility and growth. J Cell Biol 119: 629-41. 
Chan, A.M., H.W. King, E.A. Deakin, P.R. Tempest, J. Hilkens, V. Kroezen, D.R. 
Edwards, A.J. Wills, P. Brookes, and C.S. Cooper. 1988. Characterization 
of the mouse met proto-oncogene. Oncogene 2: 593-9. 
Chen, X., S. Bonne, M. Hatzfeld, F. van Roy, and K.J. Green. 2002. Protein 
binding and functional characterization of plakophilin 2. Evidence for its 
diverse roles in desmosomes and beta -catenin signaling. J Biol Chem 
277: 10512-22. 
Christensen, J.G., J. Burrows, and R. Salgia. 2005. c-Met as a target for human 
cancer and characterization of inhibitors for therapeutic intervention. 
Cancer Lett 225: 1-26. 
REFERENCES   
 60 
Colombatti, A., E.N. Hughes, B.A. Taylor, and J.T. August. 1982. Gene for a 
major cell surface glycoprotein of mouse macrophages and other 
phagocytic cells is on chromosome 2. Proc Natl Acad Sci U S A 79: 1926-
9. 
Cooper, C.S., D.G. Blair, M.K. Oskarsson, M.A. Tainsky, L.A. Eader, and G.F. 
Vande Woude. 1984a. Characterization of human transforming genes 
from chemically transformed, teratocarcinoma, and pancreatic carcinoma 
cell lines. Cancer Res 44: 1-10. 
Cooper, C.S., M. Park, D.G. Blair, M.A. Tainsky, K. Huebner, C.M. Croce, and 
G.F. Vande Woude. 1984b. Molecular cloning of a new transforming gene 
from a chemically transformed human cell line. Nature 311: 29-33. 
Dalchau, R., J. Kirkley, and J.W. Fabre. 1980. Monoclonal antibody to a human 
leukocyte-specific membrane glycoprotein probably homologous to the 
leukocyte-common (L-C) antigen of the rat. Eur J Immunol 10: 737-44. 
Dall, P., K.H. Heider, H.P. Sinn, P. Skroch-Angel, G. Adolf, M. Kaufmann, P. 
Herrlich, and H. Ponta. 1995. Comparison of immunohistochemistry and 
RT-PCR for detection of CD44v-expression, a new prognostic factor in 
human breast cancer. Int J Cancer 60: 471-7. 
De Marzo, A.M., C. Bradshaw, J. Sauvageot, J.I. Epstein, and G.J. Miller. 1998. 
CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation 
to Gleason grade and cytoarchitecture. Prostate 34: 162-8. 
Derksen, P.W., R.M. Keehnen, L.M. Evers, M.H. van Oers, M. Spaargaren, and 
S.T. Pals. 2002. Cell surface proteoglycan syndecan-1 mediates 
hepatocyte growth factor binding and promotes Met signaling in multiple 
myeloma. Blood 99: 1405-10. 
Di Renzo, M.F., R.P. Narsimhan, M. Olivero, S. Bretti, S. Giordano, E. Medico, P. 
Gaglia, P. Zara, and P.M. Comoglio. 1991. Expression of the Met/HGF 
receptor in normal and neoplastic human tissues. Oncogene 6: 1997-
2003. 
REFERENCES   
 61 
Do, Y., A.Q. Rafi-Janajreh, R.J. McKallip, P.S. Nagarkatti, and M. Nagarkatti. 
2003. Combined deficiency in CD44 and Fas leads to exacerbation of 
lymphoproliferative and autoimmune disease. Int Immunol 15: 1327-40. 
Eichbaum, M.H., T.M. de Rossi, S. Kaul, T. Bruckner, A. Schneeweiss, and C. 
Sohn. 2006. Serum Levels of Hepatocyte Growth Factor/Scatter Factor in 
Patients with Liver Metastases from Breast Cancer. Tumour Biol 28: 36-
44. 
English, N.M., J.F. Lesley, and R. Hyman. 1998. Site-specific de-N-glycosylation 
of CD44 can activate hyaluronan binding, and CD44 activation states 
show distinct threshold densities for hyaluronan binding. Cancer Res 58: 
3736-42. 
Entwistle, J., C.L. Hall, and E.A. Turley. 1996. HA receptors: regulators of 
signalling to the cytoskeleton. J Cell Biochem 61: 569-77. 
Fan, S., Y.X. Ma, M. Gao, R.Q. Yuan, Q. Meng, I.D. Goldberg, and E.M. Rosen. 
2001. The multisubstrate adapter Gab1 regulates hepatocyte growth 
factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol 
Cell Biol 21: 4968-84. 
Fenderson, B.A., I. Stamenkovic, and A. Aruffo. 1993. Localization of hyaluronan 
in mouse embryos during implantation, gastrulation and organogenesis. 
Differentiation 54: 85-98. 
Ferracini, R., P. Longati, L. Naldini, E. Vigna, and P.M. Comoglio. 1991. 
Identification of the major autophosphorylation site of the Met/hepatocyte 
growth factor receptor tyrosine kinase. J Biol Chem 266: 19558-64. 
Fievet, B.T., A. Gautreau, C. Roy, L. Del Maestro, P. Mangeat, D. Louvard, and 
M. Arpin. 2004. Phosphoinositide binding and phosphorylation act 
sequentially in the activation mechanism of ezrin. J Cell Biol 164: 653-9. 
Fixman, E.D., M. Holgado-Madruga, L. Nguyen, D.M. Kamikura, T.M. Fournier, 
A.J. Wong, and M. Park. 1997. Efficient cellular transformation by the Met 
oncoprotein requires a functional Grb2 binding site and correlates with 
phosphorylation of the Grb2-associated proteins, Cbl and Gab1. J Biol 
Chem 272: 20167-72. 
REFERENCES   
 62 
Forsberg, U.H., M.M. Ala-Kapee, S. Jalkanen, L.C. Andersson, and J. Schroder. 
1989. The gene for human lymphocyte homing receptor is located on 
chromosome 11. Eur J Immunol 19: 409-12. 
Foster, L.C., B.M. Arkonac, N.E. Sibinga, C. Shi, M.A. Perrella, and E. Haber. 
1998. Regulation of CD44 gene expression by the proinflammatory 
cytokine interleukin-1beta in vascular smooth muscle cells. J Biol Chem 
273: 20341-6. 
Furge, K.A., Y.W. Zhang, and G.F. Vande Woude. 2000. Met receptor tyrosine 
kinase: enhanced signaling through adapter proteins. Oncogene 19: 5582-
9. 
Gao, C.F. and G.F. Vande Woude. 2005. HGF/SF-Met signaling in tumor 
progression. Cell Res 15: 49-51. 
Gardiner, E.E. and S.E. D'Souza. 1999. Sequences within fibrinogen and 
intercellular adhesion molecule-1 (ICAM-1) modulate signals required for 
mitogenesis. J Biol Chem 274: 11930-6. 
Gherardi, E., J. Gray, M. Stoker, M. Perryman, and R. Furlong. 1989. Purification 
of scatter factor, a fibroblast-derived basic protein that modulates epithelial 
interactions and movement. Proc Natl Acad Sci U S A 86: 5844-8. 
Gherardi, E., S. Sandin, M.V. Petoukhov, J. Finch, M.E. Youles, L.G. Ofverstedt, 
R.N. Miguel, T.L. Blundell, G.F. Vande Woude, U. Skoglund, and D.I. 
Svergun. 2006. Structural basis of hepatocyte growth factor/scatter factor 
and MET signalling. Proc Natl Acad Sci U S A 103: 4046-51. 
Gherardi, E., M.E. Youles, R.N. Miguel, T.L. Blundell, L. Iamele, J. Gough, A. 
Bandyopadhyay, G. Hartmann, and P.J. Butler. 2003. Functional map and 
domain structure of MET, the product of the c-met protooncogene and 
receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U 
S A 100: 12039-44. 
Giordano, S., S. Corso, P. Conrotto, S. Artigiani, G. Gilestro, D. Barberis, L. 
Tamagnone, and P.M. Comoglio. 2002. The semaphorin 4D receptor 
controls invasive growth by coupling with Met. Nat Cell Biol 4: 720-4. 
REFERENCES   
 63 
Giordano, S., M.F. Di Renzo, R.P. Narsimhan, C.S. Cooper, C. Rosa, and P.M. 
Comoglio. 1989a. Biosynthesis of the protein encoded by the c-met proto-
oncogene. Oncogene 4: 1383-8. 
Giordano, S., C. Ponzetto, M.F. Di Renzo, C.S. Cooper, and P.M. Comoglio. 
1989b. Tyrosine kinase receptor indistinguishable from the c-met protein. 
Nature 339: 155-6. 
Goldstein, L.A., D.F. Zhou, L.J. Picker, C.N. Minty, R.F. Bargatze, J.F. Ding, and 
E.C. Butcher. 1989. A human lymphocyte homing receptor, the hermes 
antigen, is related to cartilage proteoglycan core and link proteins. Cell 56: 
1063-72. 
Granes, F., C. Berndt, C. Roy, P. Mangeat, M. Reina, and S. Vilaro. 2003. 
Identification of a novel Ezrin-binding site in syndecan-2 cytoplasmic 
domain. FEBS Lett 547: 212-6. 
Granes, F., J.M. Urena, N. Rocamora, and S. Vilaro. 2000. Ezrin links syndecan-
2 to the cytoskeleton. J Cell Sci 113 ( Pt 7): 1267-76. 
Graziani, A., D. Gramaglia, L.C. Cantley, and P.M. Comoglio. 1991. The tyrosine-
phosphorylated hepatocyte growth factor/scatter factor receptor 
associates with phosphatidylinositol 3-kinase. J Biol Chem 266: 22087-90. 
Graziani, A., D. Gramaglia, P. dalla Zonca, and P.M. Comoglio. 1993. 
Hepatocyte growth factor/scatter factor stimulates the Ras-guanine 
nucleotide exchanger. J Biol Chem 268: 9165-8. 
Grossmann, K.S., C. Grund, J. Huelsken, M. Behrend, B. Erdmann, W.W. 
Franke, and W. Birchmeier. 2004. Requirement of plakophilin 2 for heart 
morphogenesis and cardiac junction formation. J Cell Biol 167: 149-60. 
Gual, P., S. Giordano, T.A. Williams, S. Rocchi, E. Van Obberghen, and P.M. 
Comoglio. 2000. Sustained recruitment of phospholipase C-gamma to 
Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 
19: 1509-18. 
Gunthert, U., M. Hofmann, W. Rudy, S. Reber, M. Zoller, I. Haussmann, S. 
Matzku, A. Wenzel, H. Ponta, and P. Herrlich. 1991. A new variant of 
REFERENCES   
 64 
glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 
65: 13-24. 
Guo, Y.J., S.C. Lin, J.H. Wang, M. Bigby, and M.S. Sy. 1994. Palmitoylation of 
CD44 interferes with CD3-mediated signaling in human T lymphocytes. Int 
Immunol 6: 213-21. 
Halaban, R., J.S. Rubin, and W. White. 1993. met and HGF-SF in normal 
melanocytes and melanoma cells. Exs 65: 329-39. 
Hallahan, D.E. and S. Virudachalam. 1997. Intercellular adhesion molecule 1 
knockout abrogates radiation induced pulmonary inflammation. Proc Natl 
Acad Sci U S A 94: 6432-7. 
Hamada, J., Y. Sawamura, and E.G. Van Meir. 1998. CD44 expression and 
growth factors. Front Biosci 3: d657-64. 
Hart, I.R., M. Birch, and J.F. Marshall. 1991. Cell adhesion receptor expression 
during melanoma progression and metastasis. Cancer Metastasis Rev 10: 
115-28. 
Hartmann, G., L. Naldini, K.M. Weidner, M. Sachs, E. Vigna, P.M. Comoglio, and 
W. Birchmeier. 1992. A functional domain in the heavy chain of scatter 
factor/hepatocyte growth factor binds the c-Met receptor and induces cell 
dissociation but not mitogenesis. Proc Natl Acad Sci U S A 89: 11574-8. 
Hartmann, G., T. Prospero, V. Brinkmann, C. Ozcelik, G. Winter, J. Hepple, S. 
Batley, F. Bladt, M. Sachs, C. Birchmeier, W. Birchmeier, and E. Gherardi. 
1998. Engineered mutants of HGF/SF with reduced binding to heparan 
sulphate proteoglycans, decreased clearance and enhanced activity in 
vivo. Curr Biol 8: 125-34. 
Hatzfeld, M. 2007. Plakophilins: Multifunctional proteins or just regulators of 
desmosomal adhesion? Biochim Biophys Acta 1773: 69-77. 
Heiska, L., K. Alfthan, M. Gronholm, P. Vilja, A. Vaheri, and O. Carpen. 1998. 
Association of ezrin with intercellular adhesion molecule-1 and -2 (ICAM-1 
and ICAM-2). Regulation by phosphatidylinositol 4, 5-bisphosphate. J Biol 
Chem 273: 21893-900. 
REFERENCES   
 65 
Henke, C.A., U. Roongta, D.J. Mickelson, J.R. Knutson, and J.B. McCarthy. 
1996. CD44-related chondroitin sulfate proteoglycan, a cell surface 
receptor implicated with tumor cell invasion, mediates endothelial cell 
migration on fibrinogen and invasion into a fibrin matrix. J Clin Invest 97: 
2541-52. 
Hiramitsu, T., T. Yasuda, H. Ito, M. Shimizu, S.M. Julovi, T. Kakinuma, M. 
Akiyoshi, M. Yoshida, and T. Nakamura. 2006. Intercellular adhesion 
molecule-1 mediates the inhibitory effects of hyaluronan on interleukin-
1beta-induced matrix metalloproteinase production in rheumatoid synovial 
fibroblasts via down-regulation of NF-kappaB and p38. Rheumatology 
(Oxford) 45: 824-32. 
Hirao, M., N. Sato, T. Kondo, S. Yonemura, M. Monden, T. Sasaki, Y. Takai, and 
S. Tsukita. 1996. Regulation mechanism of ERM (ezrin/radixin/moesin) 
protein/plasma membrane association: possible involvement of 
phosphatidylinositol turnover and Rho-dependent signaling pathway. J 
Cell Biol 135: 37-51. 
Hofmann, M., W. Rudy, U. Gunthert, S.G. Zimmer, V. Zawadzki, M. Zoller, R.B. 
Lichtner, P. Herrlich, and H. Ponta. 1993. A link between ras and 
metastatic behavior of tumor cells: ras induces CD44 promoter activity and 
leads to low-level expression of metastasis-specific variants of CD44 in 
CREF cells. Cancer Res 53: 1516-21. 
Holmes, O., S. Pillozzi, J.A. Deakin, F. Carafoli, L. Kemp, P.J. Butler, M. Lyon, 
and E. Gherardi. 2007. Insights into the Structure/Function of Hepatocyte 
Growth Factor/Scatter Factor from Studies with Individual Domains. J Mol 
Biol. 
Hudson, D.L., J. Sleeman, and F.M. Watt. 1995. CD44 is the major peanut lectin-
binding glycoprotein of human epidermal keratinocytes and plays a role in 
intercellular adhesion. J Cell Sci 108 ( Pt 5): 1959-70. 
Huet, S., H. Groux, B. Caillou, H. Valentin, A.M. Prieur, and A. Bernard. 1989. 
CD44 contributes to T cell activation. J Immunol 143: 798-801. 
REFERENCES   
 66 
Huff, J.L., M.A. Jelinek, C.A. Borgman, T.J. Lansing, and J.T. Parsons. 1993. 
The protooncogene c-sea encodes a transmembrane protein-tyrosine 
kinase related to the Met/hepatocyte growth factor/scatter factor receptor. 
Proc Natl Acad Sci U S A 90: 6140-4. 
Ishibashi, K., S. Sasaki, H. Sakamoto, Y. Nakamura, T. Hata, T. Nakamura, and 
F. Marumo. 1992. Hepatocyte growth factor is a paracrine factor for renal 
epithelial cells: stimulation of DNA synthesis and NA,K-ATPase activity. 
Biochem Biophys Res Commun 182: 960-5. 
Ivetic, A. and A.J. Ridley. 2004. Ezrin/radixin/moesin proteins and Rho GTPase 
signalling in leucocytes. Immunology 112: 165-76. 
Jalkanen, S., S. Saari, H. Kalimo, K. Lammintausta, E. Vainio, R. Leino, A.M. 
Duijvestijn, and K. Kalimo. 1990. Lymphocyte migration into the skin: the 
role of lymphocyte homing receptor (CD44) and endothelial cell antigen 
(HECA-452). J Invest Dermatol 94: 786-92. 
Jeffers, M., M. Fiscella, C.P. Webb, M. Anver, S. Koochekpour, and G.F. Vande 
Woude. 1998. The mutationally activated Met receptor mediates motility 
and metastasis. Proc Natl Acad Sci U S A 95: 14417-22. 
Jeffers, M., L. Schmidt, N. Nakaigawa, C.P. Webb, G. Weirich, T. Kishida, B. 
Zbar, and G.F. Vande Woude. 1997. Activating mutations for the met 
tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 94: 
11445-50. 
Kajita, M., Y. Itoh, T. Chiba, H. Mori, A. Okada, H. Kinoh, and M. Seiki. 2001. 
Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes 
cell migration. J Cell Biol 153: 893-904. 
Kan, M., G.H. Zhang, R. Zarnegar, G. Michalopoulos, Y. Myoken, W.L. 
McKeehan, and J.I. Stevens. 1991. Hepatocyte growth 
factor/hepatopoietin A stimulates the growth of rat kidney proximal tubule 
epithelial cells (RPTE), rat nonparenchymal liver cells, human melanoma 
cells, mouse keratinocytes and stimulates anchorage-independent growth 
of SV-40 transformed RPTE. Biochem Biophys Res Commun 174: 331-7. 
REFERENCES   
 67 
Kaya, G., I. Rodriguez, J.L. Jorcano, P. Vassalli, and I. Stamenkovic. 1997. 
Selective suppression of CD44 in keratinocytes of mice bearing an 
antisense CD44 transgene driven by a tissue-specific promoter disrupts 
hyaluronate metabolism in the skin and impairs keratinocyte proliferation. 
Genes Dev 11: 996-1007. 
Khaldoyanidi, S., A. Denzel, and M. Zoller. 1996. Requirement for CD44 in 
proliferation and homing of hematopoietic precursor cells. J Leukoc Biol 
60: 579-92. 
Khaldoyanidi, S., D. Schnabel, N. Fohr, and M. Zoller. 1997. Functional activity of 
CD44 isoforms in haemopoiesis of the rat. Br J Haematol 96: 31-45. 
Khwaja, A., K. Lehmann, B.M. Marte, and J. Downward. 1998. Phosphoinositide 
3-kinase induces scattering and tubulogenesis in epithelial cells through a 
novel pathway. J Biol Chem 273: 18793-801. 
Kohda, D., C.J. Morton, A.A. Parkar, H. Hatanaka, F.M. Inagaki, I.D. Campbell, 
and A.J. Day. 1996. Solution structure of the link module: a hyaluronan-
binding domain involved in extracellular matrix stability and cell migration. 
Cell 86: 767-75. 
Lacy, B.E. and C.B. Underhill. 1987. The hyaluronate receptor is associated with 
actin filaments. J Cell Biol 105: 1395-404. 
Legg, J.W. and C.M. Isacke. 1998. Identification and functional analysis of the 
ezrin-binding site in the hyaluronan receptor, CD44. Curr Biol 8: 705-8. 
Legg, J.W., C.A. Lewis, M. Parsons, T. Ng, and C.M. Isacke. 2002. A novel PKC-
regulated mechanism controls CD44 ezrin association and directional cell 
motility. Nat Cell Biol 4: 399-407. 
Lin, Y.C., C.T. Shun, M.S. Wu, and C.C. Chen. 2006. A Novel Anticancer Effect 
of Thalidomide: Inhibition of Intercellular Adhesion Molecule-1-Mediated 
Cell Invasion and Metastasis through Suppression of Nuclear Factor-
{kappa}B. Clin Cancer Res 12: 7165-7173. 
Lisignoli, G., F. Grassi, N. Zini, S. Toneguzzi, A. Piacentini, D. Guidolin, C. 
Bevilacqua, and A. Facchini. 2001. Anti-Fas-induced apoptosis in 
chondrocytes reduced by hyaluronan: evidence for CD44 and CD54 
REFERENCES   
 68 
(intercellular adhesion molecule 1) invovement. Arthritis Rheum 44: 1800-
7. 
Liu, D. and M.S. Sy. 1996. A cysteine residue located in the transmembrane 
domain of CD44 is important in binding of CD44 to hyaluronic acid. J Exp 
Med 183: 1987-94. 
Lokeshwar, V.B. and L.Y. Bourguignon. 1991. Post-translational protein 
modification and expression of ankyrin-binding site(s) in GP85 (Pgp-
1/CD44) and its biosynthetic precursors during T-lymphoma membrane 
biosynthesis. J Biol Chem 266: 17983-9. 
Lokker, N.A., M.R. Mark, E.A. Luis, G.L. Bennett, K.A. Robbins, J.B. Baker, and 
P.J. Godowski. 1992. Structure-function analysis of hepatocyte growth 
factor: identification of variants that lack mitogenic activity yet retain high 
affinity receptor binding. Embo J 11: 2503-10. 
Longati, P., A. Bardelli, C. Ponzetto, L. Naldini, and P.M. Comoglio. 1994. 
Tyrosines1234-1235 are critical for activation of the tyrosine kinase 
encoded by the MET proto-oncogene (HGF receptor). Oncogene 9: 49-57. 
Louvet-Vallee, S. 2000. ERM proteins: from cellular architecture to cell signaling. 
Biol Cell 92: 305-16. 
Luo, Y.Q., M.C. Wu, and W.M. Cong. 1999. Gene expression of hepatocyte 
growth factor and its receptor in HCC and nontumorous liver tissues. 
World J Gastroenterol 5: 119-121. 
Machide, M., A. Hashigasako, K. Matsumoto, and T. Nakamura. 2006. Contact 
inhibition of hepatocyte growth regulated by functional association of the 
c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine 
phosphatase. J Biol Chem 281: 8765-72. 
Mackay, C.R., J.F. Maddox, G.L. Wijffels, I.R. Mackay, and I.D. Walker. 1988. 
Characterization of a 95,000 molecule on sheep leucocytes homologous 
to murine Pgp-1 and human CD44. Immunology 65: 93-9. 
Mackay, C.R., H.J. Terpe, R. Stauder, W.L. Marston, H. Stark, and U. Gunthert. 
1994. Expression and modulation of CD44 variant isoforms in humans. J 
Cell Biol 124: 71-82. 
REFERENCES   
 69 
Maniatis, T., Fritsch, E.F. and Sambrook, J. 1989. Molecular cloning: a laboratory 
manual. Cold Spring Harbor, Cold Spring Harbor Laboratory, NY 
Maina, F., F. Casagranda, E. Audero, A. Simeone, P.M. Comoglio, R. Klein, and 
C. Ponzetto. 1996. Uncoupling of Grb2 from the Met receptor in vivo 
reveals complex roles in muscle development. Cell 87: 531-42. 
Maina, F., G. Pante, F. Helmbacher, R. Andres, A. Porthin, A.M. Davies, C. 
Ponzetto, and R. Klein. 2001. Coupling Met to specific pathways results in 
distinct developmental outcomes. Mol Cell 7: 1293-306. 
Maroun, C.R., M.A. Naujokas, M. Holgado-Madruga, A.J. Wong, and M. Park. 
2000. The tyrosine phosphatase SHP-2 is required for sustained activation 
of extracellular signal-regulated kinase and epithelial morphogenesis 
downstream from the met receptor tyrosine kinase. Mol Cell Biol 20: 8513-
25. 
Matzke, A., P. Herrlich, H. Ponta, and V. Orian-Rousseau. 2005. A five-amino-
acid peptide blocks Met- and Ron-dependent cell migration. Cancer Res 
65: 6105-10. 
Maulik, G., A. Shrikhande, T. Kijima, P.C. Ma, P.T. Morrison, and R. Salgia. 
2002. Role of the hepatocyte growth factor receptor, c-Met, in 
oncogenesis and potential for therapeutic inhibition. Cytokine Growth 
Factor Rev 13: 41-59. 
McCourt, P.A., B. Ek, N. Forsberg, and S. Gustafson. 1994. Intercellular 
adhesion molecule-1 is a cell surface receptor for hyaluronan. J Biol Chem 
269: 30081-4. 
Mertens, C., C. Kuhn, and W.W. Franke. 1996. Plakophilins 2a and 2b: 
constitutive proteins of dual location in the karyoplasm and the 
desmosomal plaque. J Cell Biol 135: 1009-25. 
Miyake, K., K.L. Medina, S. Hayashi, S. Ono, T. Hamaoka, and P.W. Kincade. 
1990. Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in 
long-term bone marrow cultures. J Exp Med 171: 477-88. 
REFERENCES   
 70 
Mood, K., C. Saucier, Y.S. Bong, H.S. Lee, M. Park, and I.O. Daar. 2006. Gab1 
is required for cell cycle transition, cell proliferation, and transformation 
induced by an oncogenic met receptor. Mol Biol Cell 17: 3717-28. 
Morrison, H., L.S. Sherman, J. Legg, F. Banine, C. Isacke, C.A. Haipek, D.H. 
Gutmann, H. Ponta, and P. Herrlich. 2001. The NF2 tumor suppressor 
gene product, merlin, mediates contact inhibition of growth through 
interactions with CD44. Genes Dev 15: 968-80. 
Morrison, H., T. Sperka, J. Manent, M. Giovannini, H. Ponta, and P. Herrlich. 
2007. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the 
activation of Ras and Rac. Cancer Res 67: 520-7. 
Nakamura, T., K. Nawa, and A. Ichihara. 1984. Partial purification and 
characterization of hepatocyte growth factor from serum of 
hepatectomized rats. Biochem Biophys Res Commun 122: 1450-9. 
Nakamura, T., K. Nawa, A. Ichihara, N. Kaise, and T. Nishino. 1987. Purification 
and subunit structure of hepatocyte growth factor from rat platelets. FEBS 
Lett 224: 311-6. 
Nakamura, T., T. Nishizawa, M. Hagiya, T. Seki, M. Shimonishi, A. Sugimura, K. 
Tashiro, and S. Shimizu. 1989. Molecular cloning and expression of 
human hepatocyte growth factor. Nature 342: 440-3. 
Naldini, L., E. Vigna, R. Ferracini, P. Longati, L. Gandino, M. Prat, and P.M. 
Comoglio. 1991a. The tyrosine kinase encoded by the MET proto-
oncogene is activated by autophosphorylation. Mol Cell Biol 11: 1793-803. 
Naldini, L., E. Vigna, R.P. Narsimhan, G. Gaudino, R. Zarnegar, G.K. 
Michalopoulos, and P.M. Comoglio. 1991b. Hepatocyte growth factor 
(HGF) stimulates the tyrosine kinase activity of the receptor encoded by 
the proto-oncogene c-MET. Oncogene 6: 501-4. 
Naldini, L., K.M. Weidner, E. Vigna, G. Gaudino, A. Bardelli, C. Ponzetto, R.P. 
Narsimhan, G. Hartmann, R. Zarnegar, G.K. Michalopoulos, and et al. 
1991c. Scatter factor and hepatocyte growth factor are indistinguishable 
ligands for the MET receptor. Embo J 10: 2867-78. 
REFERENCES   
 71 
Naor, D., R.V. Sionov, and D. Ish-Shalom. 1997. CD44: structure, function, and 
association with the malignant process. Adv Cancer Res 71: 241-319. 
Nedvetzki, S., E. Gonen, N. Assayag, R. Reich, R.O. Williams, R.L. Thurmond, 
J.F. Huang, B.A. Neudecker, F.S. Wang, E.A. Turley, and D. Naor. 2004. 
RHAMM, a receptor for hyaluronan-mediated motility, compensates for 
CD44 in inflamed CD44-knockout mice: a different interpretation of 
redundancy. Proc Natl Acad Sci U S A 101: 18081-6. 
Nelson, R.M., A. Venot, M.P. Bevilacqua, R.J. Linhardt, and I. Stamenkovic. 
1995. Carbohydrate-protein interactions in vascular biology. Annu Rev 
Cell Dev Biol 11: 601-31. 
Okigaki, M., M. Komada, Y. Uehara, K. Miyazawa, and N. Kitamura. 1992. 
Functional characterization of human hepatocyte growth factor mutants 
obtained by deletion of structural domains. Biochemistry 31: 9555-61. 
Orian-Rousseau, V., L. Chen, J.P. Sleeman, P. Herrlich, and H. Ponta. 2002. 
CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes 
Dev 16: 3074-86. 
Orian-Rousseau, V., H. Morrison, A. Matzke, T. Kastilan, G. Pace, P. Herrlich, 
and H. Ponta. 2007. Hepatocyte growth factor-induced Ras activation 
requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 
18: 76-83. 
Park, M., M. Dean, C.S. Cooper, M. Schmidt, S.J. O'Brien, D.G. Blair, and G.F. 
Vande Woude. 1986. Mechanism of met oncogene activation. Cell 45: 
895-904. 
Peck, D. and C.M. Isacke. 1998. Hyaluronan-dependent cell migration can be 
blocked by a CD44 cytoplasmic domain peptide containing a 
phosphoserine at position 325. J Cell Sci 111 ( Pt 11): 1595-601. 
Pelicci, G., S. Giordano, Z. Zhen, A.E. Salcini, L. Lanfrancone, A. Bardelli, G. 
Panayotou, M.D. Waterfield, C. Ponzetto, P.G. Pelicci, and et al. 1995. 
The motogenic and mitogenic responses to HGF are amplified by the Shc 
adaptor protein. Oncogene 10: 1631-8. 
REFERENCES   
 72 
Picker, L.J., J. De los Toyos, M.J. Telen, B.F. Haynes, and E.C. Butcher. 1989. 
Monoclonal antibodies against the CD44 [In(Lu)-related p80], and Pgp-1 
antigens in man recognize the Hermes class of lymphocyte homing 
receptors. J Immunol 142: 2046-51. 
Ponta, H., L. Sherman, and P.A. Herrlich. 2003. CD44: from adhesion molecules 
to signalling regulators. Nat Rev Mol Cell Biol 4: 33-45. 
Ponta, H., D. Wainwright, and P. Herrlich. 1998. The CD44 protein family. Int J 
Biochem Cell Biol 30: 299-305. 
Ponzetto, C., A. Bardelli, Z. Zhen, F. Maina, P. dalla Zonca, S. Giordano, A. 
Graziani, G. Panayotou, and P.M. Comoglio. 1994. A multifunctional 
docking site mediates signaling and transformation by the hepatocyte 
growth factor/scatter factor receptor family. Cell 77: 261-71. 
Ponzetto, C., Z. Zhen, E. Audero, F. Maina, A. Bardelli, M.L. Basile, S. Giordano, 
R. Narsimhan, and P. Comoglio. 1996. Specific uncoupling of GRB2 from 
the Met receptor. Differential effects on transformation and motility. J Biol 
Chem 271: 14119-23. 
Protin, U., T. Schweighoffer, W. Jochum, and F. Hilberg. 1999. CD44-deficient 
mice develop normally with changes in subpopulations and recirculation of 
lymphocyte subsets. J Immunol 163: 4917-23. 
Pure, E. and C.A. Cuff. 2001. A crucial role for CD44 in inflammation. Trends Mol 
Med 7: 213-21. 
Rafi-Janajreh, A.Q., D. Chen, R. Schmits, T.W. Mak, R.L. Grayson, D.P. 
Sponenberg, M. Nagarkatti, and P.S. Nagarkatti. 1999. Evidence for the 
involvement of CD44 in endothelial cell injury and induction of vascular 
leak syndrome by IL-2. J Immunol 163: 1619-27. 
Reeder, J.A., D.C. Gotley, M.D. Walsh, J. Fawcett, and T.M. Antalis. 1998. 
Expression of antisense CD44 variant 6 inhibits colorectal tumor 
metastasis and tumor growth in a wound environment. Cancer Res 58: 
3719-26. 
REFERENCES   
 73 
Ristamaki, R., H. Joensuu, M. Salmi, and S. Jalkanen. 1994. Serum CD44 in 
malignant lymphoma: an association with treatment response. Blood 84: 
238-43. 
Rodrigues, G.A. and M. Park. 1993. Dimerization mediated through a leucine 
zipper activates the oncogenic potential of the met receptor tyrosine 
kinase. Mol Cell Biol 13: 6711-22. 
Ronsin, C., F. Muscatelli, M.G. Mattei, and R. Breathnach. 1993. A novel putative 
receptor protein tyrosine kinase of the met family. Oncogene 8: 1195-202. 
Rosette, C., R.B. Roth, P. Oeth, A. Braun, S. Kammerer, J. Ekblom, and M.F. 
Denissenko. 2005. Role of ICAM1 in invasion of human breast cancer 
cells. Carcinogenesis 26: 943-50. 
Rubin, J.S., A.M. Chan, D.P. Bottaro, W.H. Burgess, W.G. Taylor, A.C. Cech, 
D.W. Hirschfield, J. Wong, T. Miki, P.W. Finch, and et al. 1991. A broad-
spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte 
growth factor. Proc Natl Acad Sci U S A 88: 415-9. 
Rudy, W., M. Hofmann, R. Schwartz-Albiez, M. Zoller, K.H. Heider, H. Ponta, and 
P. Herrlich. 1993. The two major CD44 proteins expressed on a metastatic 
rat tumor cell line are derived from different splice variants: each one 
individually suffices to confer metastatic behavior. Cancer Res 53: 1262-8. 
Ruiz, P., C. Schwarzler, and U. Gunthert. 1995. CD44 isoforms during 
differentiation and development. Bioessays 17: 17-24. 
Sachs, M., H. Brohmann, D. Zechner, T. Muller, J. Hulsken, I. Walther, U. 
Schaeper, C. Birchmeier, and W. Birchmeier. 2000. Essential role of Gab1 
for signaling by the c-Met receptor in vivo. J Cell Biol 150: 1375-84. 
Schmidt, C., F. Bladt, S. Goedecke, V. Brinkmann, W. Zschiesche, M. Sharpe, E. 
Gherardi, and C. Birchmeier. 1995. Scatter factor/hepatocyte growth factor 
is essential for liver development. Nature 373: 699-702. 
Schmits, R., J. Filmus, N. Gerwin, G. Senaldi, F. Kiefer, T. Kundig, A. Wakeham, 
A. Shahinian, C. Catzavelos, J. Rak, C. Furlonger, A. Zakarian, J.J. 
Simard, P.S. Ohashi, C.J. Paige, J.C. Gutierrez-Ramos, and T.W. Mak. 
REFERENCES   
 74 
1997. CD44 regulates hematopoietic progenitor distribution, granuloma 
formation, and tumorigenicity. Blood 90: 2217-33. 
Screaton, G.R., M.V. Bell, J.I. Bell, and D.G. Jackson. 1993. The identification of 
a new alternative exon with highly restricted tissue expression in 
transcripts encoding the mouse Pgp-1 (CD44) homing receptor. 
Comparison of all 10 variable exons between mouse, human, and rat. J 
Biol Chem 268: 12235-8. 
Screaton, G.R., M.V. Bell, D.G. Jackson, F.B. Cornelis, U. Gerth, and J.I. Bell. 
1992. Genomic structure of DNA encoding the lymphocyte homing 
receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl 
Acad Sci U S A 89: 12160-4. 
Seelentag, W.K., R. Flury, M. Schmid, P. Komminoth, P. Saremaslani, U. 
Gunthert, P.U. Heitz, and J. Roth. 1995. [Expression of CD44 isoforms in 
normal human liver and also in regenerative and neoplastic liver changes]. 
Verh Dtsch Ges Pathol 79: 144-7. 
Sherman, L., D. Wainwright, H. Ponta, and P. Herrlich. 1998. A splice variant of 
CD44 expressed in the apical ectodermal ridge presents fibroblast growth 
factors to limb mesenchyme and is required for limb outgrowth. Genes 
Dev 12: 1058-71. 
Shimizu, M., T. Yasuda, T. Nakagawa, E. Yamashita, S.M. Julovi, T. Hiramitsu, 
and T. Nakamura. 2003. Hyaluronan inhibits matrix metalloproteinase-1 
production by rheumatoid synovial fibroblasts stimulated by 
proinflammatory cytokines. J Rheumatol 30: 1164-72. 
Shimizu, Y., G.A. Van Seventer, R. Siraganian, L. Wahl, and S. Shaw. 1989. 
Dual role of the CD44 molecule in T cell adhesion and activation. J 
Immunol 143: 2457-63. 
Shtivelman, E. and J.M. Bishop. 1991. Expression of CD44 is repressed in 
neuroblastoma cells. Mol Cell Biol 11: 5446-53. 
Singh-Kaw, P., R. Zarnegar, and J.M. Siegfried. 1995. Stimulatory effects of 
hepatocyte growth factor on normal and neoplastic human bronchial 
epithelial cells. Am J Physiol 268: L1012-20. 
REFERENCES   
 75 
Sleeman, J., J. Moll, L. Sherman, P. Dall, S.T. Pals, H. Ponta, and P. Herrlich. 
1995. The role of CD44 splice variants in human metastatic cancer. Ciba 
Found Symp 189: 142-51; discussion 151-6, 174-6. 
Sleeman, J.P., K. Kondo, J. Moll, H. Ponta, and P. Herrlich. 1997. Variant exons 
v6 and v7 together expand the repertoire of glycosaminoglycans bound by 
CD44. J Biol Chem 272: 31837-44. 
Son, G., T. Hirano, E. Seki, Y. Iimuro, T. Nukiwa, K. Matsumoto, T. Nakamura, 
and J. Fujimoto. 2006. Blockage of HGF/c-Met system by gene therapy 
(adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in 
mice. J Hepatol 45: 688-95. 
Sonnenberg, E., D. Meyer, K.M. Weidner, and C. Birchmeier. 1993. Scatter 
factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, 
can mediate a signal exchange between mesenchyme and epithelia 
during mouse development. J Cell Biol 123: 223-35. 
Stamenkovic, I., M. Amiot, J.M. Pesando, and B. Seed. 1989. A lymphocyte 
molecule implicated in lymph node homing is a member of the cartilage 
link protein family. Cell 56: 1057-62. 
Stoker, M., E. Gherardi, M. Perryman, and J. Gray. 1987. Scatter factor is a 
fibroblast-derived modulator of epithelial cell mobility. Nature 327: 239-42. 
Sun, J.J., X.D. Zhou, Y.K. Liu, Z.Y. Tang, J.X. Feng, G. Zhou, Q. Xue, and J. 
Chen. 1999. Invasion and metastasis of liver cancer: expression of 
intercellular adhesion molecule 1. J Cancer Res Clin Oncol 125: 28-34. 
Takahashi, K., I. Stamenkovic, M. Cutler, A. Dasgupta, and K.K. Tanabe. 1996. 
Keratan sulfate modification of CD44 modulates adhesion to hyaluronate. 
J Biol Chem 271: 9490-6. 
Takayama, H., W.J. LaRochelle, R. Sharp, T. Otsuka, P. Kriebel, M. Anver, S.A. 
Aaronson, and G. Merlino. 1997. Diverse tumorigenesis associated with 
aberrant development in mice overexpressing hepatocyte growth 
factor/scatter factor. Proc Natl Acad Sci U S A 94: 701-6. 
REFERENCES   
 76 
Teder, P., R.W. Vandivier, D. Jiang, J. Liang, L. Cohn, E. Pure, P.M. Henson, 
and P.W. Noble. 2002. Resolution of lung inflammation by CD44. Science 
296: 155-8. 
Terpe, H.J., H. Stark, P. Prehm, and U. Gunthert. 1994. CD44 variant isoforms 
are preferentially expressed in basal epithelial of non-malignant human 
fetal and adult tissues. Histochemistry 101: 79-89. 
Thorne, R.F., J.W. Legg, and C.M. Isacke. 2004. The role of the CD44 
transmembrane and cytoplasmic domains in co-ordinating adhesive and 
signalling events. J Cell Sci 117: 373-80. 
Tolg, C., M. Hofmann, P. Herrlich, and H. Ponta. 1993. Splicing choice from ten 
variant exons establishes CD44 variability. Nucleic Acids Res 21: 1225-9. 
Trusolino, L., A. Bertotti, and P.M. Comoglio. 2001. A signaling adapter function 
for alpha6beta4 integrin in the control of HGF-dependent invasive growth. 
Cell 107: 643-54. 
Tsukita, S. and S. Yonemura. 1999. Cortical actin organization: lessons from 
ERM (ezrin/radixin/moesin) proteins. J Biol Chem 274: 34507-10. 
Uehara, Y., O. Minowa, C. Mori, K. Shiota, J. Kuno, T. Noda, and N. Kitamura. 
1995. Placental defect and embryonic lethality in mice lacking hepatocyte 
growth factor/scatter factor. Nature 373: 702-5. 
Underhill, C.B., S.J. Green, P.M. Comoglio, and G. Tarone. 1987. The 
hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as 
shown by a monoclonal antibody that interferes with binding activity. J Biol 
Chem 262: 13142-6. 
van der Voort, R., T.E. Taher, V.J. Wielenga, M. Spaargaren, R. Prevo, L. Smit, 
G. David, G. Hartmann, E. Gherardi, and S.T. Pals. 1999. Heparan 
sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-
induced signal transduction through the receptor tyrosine kinase c-Met. J 
Biol Chem 274: 6499-506. 
Wainwright, D. 1998. Growth factor presentation by CD44 variant proteins. In. 
Imperial College of Science, Technology and Medicine, London. 
REFERENCES   
 77 
Washington, K., M.J. Telen, and M.R. Gottfried. 1997. Expression of cell 
adhesion molecule CD44 in primary tumors of the liver: an 
immunohistochemical study. Liver 17: 17-23. 
Watanabe, T., M. Tsuda, Y. Makino, S. Ichihara, H. Sawa, A. Minami, N. 
Mochizuki, K. Nagashima, and S. Tanaka. 2006. Adaptor molecule Crk is 
required for sustained phosphorylation of Grb2-associated binder 1 and 
hepatocyte growth factor-induced cell motility of human synovial sarcoma 
cell lines. Mol Cancer Res 4: 499-510. 
Weidner, K.M., S. Di Cesare, M. Sachs, V. Brinkmann, J. Behrens, and W. 
Birchmeier. 1996. Interaction between Gab1 and the c-Met receptor 
tyrosine kinase is responsible for epithelial morphogenesis. Nature 384: 
173-6. 
Wheatley, S.C., C.M. Isacke, and P.H. Crossley. 1993. Restricted expression of 
the hyaluronan receptor, CD44, during postimplantation mouse 
embryogenesis suggests key roles in tissue formation and patterning. 
Development 119: 295-306. 
Wielenga, V.J., R. van der Voort, J.W. Mulder, P.M. Kruyt, W.F. Weidema, J. 
Oosting, C.A. Seldenrijk, C. van Krimpen, G.J. Offerhaus, and S.T. Pals. 
1998. CD44 splice variants as prognostic markers in colorectal cancer. 
Scand J Gastroenterol 33: 82-7. 
Wittig, B.M., B. Johansson, M. Zoller, C. Schwarzler, and U. Gunthert. 2000. 
Abrogation of experimental colitis correlates with increased apoptosis in 
mice deficient for CD44 variant exon 7 (CD44v7). J Exp Med 191: 2053-
64. 
Yang, H., N. Magilnick, M. Noureddin, J.M. Mato, and S.C. Lu. 2007. Effect of 
hepatocyte growth factor on methionine adenosyltransferase genes and 
growth is cell density-dependent in HepG2 cells. J Cell Physiol 210: 766-
73. 
Yang, L., J.R. Kowalski, P. Yacono, M. Bajmoczi, S.K. Shaw, R.M. Froio, D.E. 
Golan, S.M. Thomas, and F.W. Luscinskas. 2006. Endothelial cell 
cortactin coordinates intercellular adhesion molecule-1 clustering and 
REFERENCES   
 78 
actin cytoskeleton remodeling during polymorphonuclear leukocyte 
adhesion and transmigration. J Immunol 177: 6440-9. 
Yang, Y., C.D. Jun, J.H. Liu, R. Zhang, A. Joachimiak, T.A. Springer, and J.H. 
Wang. 2004. Structural basis for dimerization of ICAM-1 on the cell 
surface. Mol Cell 14: 269-76. 
Yu, J., S. Miehlke, M.P. Ebert, J. Hoffmann, M. Breidert, B. Alpen, T. Starzynska, 
M. Stolte Prof, P. Malfertheiner, and E. Bayerdorffer. 2000. Frequency of 
TPR-MET rearrangement in patients with gastric carcinoma and in first-
degree relatives. Cancer 88: 1801-6. 
Yu, Q. and I. Stamenkovic. 1999. Localization of matrix metalloproteinase 9 to 
the cell surface provides a mechanism for CD44-mediated tumor invasion. 
Genes Dev 13: 35-48. 
Yu, Q. and I. Stamenkovic. 2000. Cell surface-localized matrix metalloproteinase-
9 proteolytically activates TGF-beta and promotes tumor invasion and 
angiogenesis. Genes Dev 14: 163-76. 
Yu, Q., B.P. Toole, and I. Stamenkovic. 1997. Induction of apoptosis of 
metastatic mammary carcinoma cells in vivo by disruption of tumor cell 
surface CD44 function. J Exp Med 186: 1985-96. 
Yu, W.H., J.F. Woessner, Jr., J.D. McNeish, and I. Stamenkovic. 2002. CD44 
anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal 
growth factor precursor and ErbB4 and regulates female reproductive 
organ remodeling. Genes Dev 16: 307-23. 
Zarnegar, R. and M.C. DeFrances. 1993. Expression of HGF-SF in normal and 
malignant human tissues. Exs 65: 181-99. 
Zeidler, A., R. Brauer, K. Thoss, J. Bahnsen, V. Heinrichs, D. Jablonski-Westrich, 
M. Wroblewski, S. Rebstock, and A. Hamann. 1995. Therapeutic effects of 
antibodies against adhesion molecules in murine collagen type II-induced 
arthritis. Autoimmunity 21: 245-52. 
Zhang, Y.W. and G.F. Vande Woude. 2003. HGF/SF-met signaling in the control 
of branching morphogenesis and invasion. J Cell Biochem 88: 408-17. 
REFERENCES   
 79 
Zhou, D.F., J.F. Ding, L.J. Picker, R.F. Bargatze, E.C. Butcher, and D.V. 
Goeddel. 1989. Molecular cloning and expression of Pgp-1. The mouse 
homolog of the human H-CAM (Hermes) lymphocyte homing receptor. J 
Immunol 143: 3390-5. 
Zhu, H., M.A. Naujokas, E.D. Fixman, K. Torossian, and M. Park. 1994. Tyrosine 
1356 in the carboxyl-terminal tail of the HGF/SF receptor is essential for 
the transduction of signals for cell motility and morphogenesis. J Biol 
Chem 269: 29943-8. 
Zoller, M., K. Herrmann, S. Buchner, S. Seiter, C. Claas, C.B. Underhill, and P. 
Moller. 1997. Transient absence of CD44 expression and delay in 
development by anti-CD44 treatment during ontogeny: a surrogate of an 










Date of birth 
Nationality 
Marital status 





Education & Qualifications 
Dec 2002-2007 
Forchungszentrum 
Karlsruhe, Institut für 
Toxikology und Genetik 
PhD thesis title: Intercellular adhesion molecule-1 (ICAM-1) a 




Project title: Identification, localisation and function of protein 
complexes in Listeria monocytogenes 
2000-2001 
University of Leicester 
MSc Molecular Genetics. Awarded Amersham Pharmacia Biotech 
Prize 
Research Project cDNA Cloning and Characterisation of MEA, a 
Putative Interacting Partner of WASP 
1995-1998 
University of Westminster 
BSc (Hons) Biochemistry & Microbiology. Lower Second Class 
degree (2:2).  
Project title: Analysis of the human p53 gene in colon cancer 
1992-1995  
Maria Fidelis Convent 
School 
A Levels Biology, Chemistry and English. 
 
 
